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Cannabis sativa L. (cannabis) is an annual dioecious plant belonging to the 
family Cannabaceae. Cannabis has a long history of human use as a medicinal 
plant, intoxicant, and ritual drug.1 Today most nations’ worldwide regard 
cannabis as an illegal drug of abuse. Despite the abuse, potential of cannabis 
research into its chemistry and pharmacology has demonstrated that it also has 
medical properties. Chemical analysis of cannabis in the 1940s and 1960s led to 
the discovery of a unique group of terpeno-phenolic secondary metabolites, 
known as cannabinoids, of which trans-(Δ)-D-9-tetrahydrocannabinol (Δ9-THC) 
was shown to be the primary psychoactive ingredient.2 Today this substances are 
known as phytocannabinoids. In the early 1990s the G-protein coupled 
cannabinoid receptors (CB) were discovered. Two types of cannabinoid receptors 
exist and their name is CB1 and CB2. They are important in mechanism of THC. 
Clinical trials into cannabis, pure cannabinoids, and synthetic analogues have 
demonstrated some effectiveness as analgesics for chronic neuropathic pain, 
appetite stimulants’ for cancer or AIDS patients, and multiple sclerosis. The 
increased medical interest in these substances has caused the development of 
various cannabis based medicines.3 
General introduction 
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The Botany of Cannabis 
The basic material of Cannabis products is the plant C. sativa L. (Figure 1). It is 
an annual, usually dioecious, more rarely monoecious, wind-pollinated herb, 
with male and female flowers developing on separate plants. It propagates from 
seed, grows vigorously in open sunny environments with well-drained soils, and 
has an abundant need for nutrients and water. It can reach up to 5 m in height in 
4–6-month. However, in modern breeding and cultivation of recreational 
Cannabis, the preferred way to propagate the plants is by cloning, using cuttings 
of the so-called mother plant. The female plants are used for this purpose, 
because they produce significantly higher amounts of psychoactive compounds 
than the male plants. The sexes of Cannabis are anatomically indistinguishable 
before they start flowering, but after that, the development of male and female 
plants varies greatly. Shorter days, or more accurately longer nights, induce the 
plant to start flowering.  
 
 
 
 
 
 
 
 
 
Figure 1. Illustration of Cannabis sativa L. ( Köhler’s Medizinal-Pflanzen, 1887, Franz Eugen 
Köhler). 
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The female plant then produces several crowded clusters of individual flowers 
(flower tops); a large one at the top of the stem and several smaller ones on each 
branch, whereas the male flowers hang in loose clusters along a relatively 
leafless upright branch. The male plants finish shedding their pollen and die 
before the seeds in the female plants ripen, that is 4–8 weeks after being 
fertilized. A large female can produce over 1 kg of seed. If the seed survives, it 
may germinate the next spring.  
According to current botanical classification, Cannabis belongs, only with 
Humulus (hops), to the small family of Cannabinaceae (also Cannabaceae or 
Cannabidaceae). Despite this close relationship, cannabinoids can only be found 
in C. sativa. The genus Humulus has been studied by scientists but in this plant 
there aren’t cannabinoids and instead a variety of the so-called bitter acids, such 
as humulone, adhumulone, and cohumulone are produced. The close relationship 
between both plant species is clearly shown by the fact that both compounds 
(cannabinoids and bitter acids, respectively) are derived from similar 
biosynthetic pathways. Furthermore, both are excreted as a resinous mixture by 
glandular hairs, mainly found on female flowers. 
The current systematic classification of Cannabis is: 
Division Angiosperms  
Class Dicotyledon  
Subclass Archichlamydeae  
Order Urticales 
Family Cannabinaceae  
Genus Cannabis Species sativa L. 
Today, more than 700 different cultivars have been described and many more are 
thought to exist.4  
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A Short History of Cannabis 
Cannabis most likely originates from Central Asia, as archeological evidence 
indicates that it was already cultivated in China for food and fiber 10.000 years 
ago. In fact, Cannabis is one of the oldest known medicinal plants and is 
described in almost every ancient handbook on plant medicine, most commonly 
in the form of a tincture or a tea. Some religions use the components of the 
Cannabis plant: for example, in Hindu legend, Cannabis is believed to be the 
favorite food of the god Shiva, because of its energizing properties. Nowadays, 
varieties of Cannabis can be found in all temperate and tropical zones, except in 
humid, tropical rain forests. The medicinal use of Cannabis was introduced in 
Europe only around 1840, by a young Irish doctor, William O’Shaughnessy, who 
served for the East India Trading Company in India, where the medicinal use of 
Cannabis was widespread.  
At the top of its popularity, more than 28 different medicinal preparations were 
available with Cannabis as active ingredient, which were recommended for 
indications as various as menstrual cramps, asthma, cough, insomnia, support of 
birth labor, migraine and throat infection. However, because no tools existed for 
quality control, it was impossible to prepare a standardized medicine, so patients 
often received a dose that was either too low, having no effect, or too high, 
resulting in serious side effects. Moreover, Cannabis extract was not water-
soluble and therefore could not be injected, moreover oral administration was 
found to be unreliable because of its slow and erratic absorption. Because of such 
drawbacks, the medicinal use of Cannabis increasingly disappeared in the 
beginning of the twentieth century, and in 1937 Cannabis was removed from the 
US pharmacopoeia, a move that was followed by most other Western countries. 
Isolation and structure elucidation of the first pure active substances from 
Cannabis has come in 1960 and so, after that, the scientists have studied for 
having medicines based on cannabis, who had positive effects.4 
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Chemical Constituents of Cannabis 
We know 538 constituents, Cannabis is one of the chemically best-studied plants. 
Most of these constituents have not yet been properly characterized for biological 
activity and so the Cannabis plant could be called a ‘neglected pharmacological 
treasure trove’. The most important classes are listed in Table 1. 
 
 
 
 
 
 
 
 
 
 
The most interesting among these constituents are those found in the secretions 
of the head cells of glandular hairs (trichomes) distributed across the surface of 
the Cannabis plant. Although trichomes can be found all over the male and 
female plants, they are particularly concentrated on the bracts that support the 
female inflorescence. Solitary resin glands, consisting of one or two dozen cells, 
most often form at the tips of slender trichome stalks that form as extensions of 
the plant surface, as shown in Figure 2. 
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Figure 2. Microscope photograph and drawing of a Cannabis resin gland, with secretory head 
cells visible underneath the transparent cannabinoid- and terpenoid- rich resin.4 
The resin excreted by the glands contains a variety of constituents, any of which 
might play a role in the biological activities of the Cannabis plant. Among these 
are terpenoids, flavonoids, and cannabinoids. Resin collects under a thin waxy 
membrane surrounding the secretory head cells. In these extracellular resin 
pockets, the secreted compounds are segregated from the secretory cells, 
protecting it from both oxidative degradation and enzymatic change. The resin 
gives a certain defense against insect and fungal attack and so they are useful for 
her protection. It has been shown that the cannabinoids, cannabigerolic acid 
(CBGA) and THCA, induce cell death through apoptosis for example in insect 
cells. It is therefore not certain how many compounds, identified from such 
materials, should be considered as artifacts, resulting from oxidation, and 
enzymatic, thermal, or other degradation. In fact, even THC itself is not produced 
by the metabolism of the Cannabis plant but rather is formed by thermal 
decarboxylation (loss of CO2) of THCA. Further degradation of THC results in 
the formation of cannabinol (CBN) or delta-8-tetrahydrocannabinol (Δ8-THC). 
Moreover many terpenoids are known to be susceptible to degradation upon 
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storage or extraction. As such, the chemical composition of any given Cannabis 
preparation depends not only on its biosynthetic composition, but also on factors 
such as age, conditions of storage, and method of extraction.4 
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Cannabinoids 
Cannabinoids are considered to be the main biologically active constituents of 
the Cannabis plant, and they can be found nowhere else in nature. This 
characteristic has underlined that the majority of biological activities, attributed 
to Cannabis, have linked to cannabinoids and more specifically to THC. The 
natural cannabinoids form a complex group of similar compounds of which 
currently 70 are known and well described. New cannabinoids, although present 
in very minor quantities have been discovered very recently (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Structures of the cannabinoids most commonly found in Cannabis plant materials. 
All cannabinoids have the (6aR,10aR)-orientation.4 
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Until the 1980s, the term cannabinoids represented by definition the group of 
typical terpenophenolic C21 compounds present in C. sativa, their carboxylic 
acids, analogues, and transformation products. A modern definition will put more 
emphasis on synthetic chemistry and on pharmacology, and would also include 
related structures or compounds that have an effect on cannabinoid receptors. 
The term ‘cannabinoids’ now represents the whole set of endogenous, natural, 
and synthetic ligands of the cannabinoid receptors, belonging to a wide variety of 
chemical families. The plant-derived cannabinoids are now often termed 
phytocannabinoids. The first cannabinoid was isolated in 1940, and its name was 
CBN (C21H26O2), but it was inactive as psychoactive compounds.4  
The most important phytocannabinoids are Δ-9-tetrahydrocannabinol (Δ9-THC) 
and cannabidiol (CBD) (Figure 4). 
 
 
Figure 4. The chemical structures of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol. 
The scientists are inspired to Δ9-tetrahydrocannabinol always, because it has a 
high affinity to CB1 and CB2 receptors and so they have projected a lot of 
molecules basing on the structures of this principle cannabinoid. When the 
scientist have begun to test Δ9-THC and the analogous compounds, they have 
seen that molecules had  psycothropic effects and so they have understood that 
the psycothropic effect of Cannabis was caused by  Δ9-tetrahydrocannabinol  and 
so the similar compounds provoked the same collateral effect.  
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For many years it has been thought that it was opportune working for eliminating 
this probleme, for example modifying  the structure of Δ9-THC and various 
analogues.5,6  
In the last years there has been a new discovery, the other principle compound of 
Cannabis, Cannabidiol, was studied by the scientists, because they have noted 
that this substance does not have the psycothropic effects of Δ9-
tetrahydrocannabinol, because it has a low affinity for cannabinoid receptors. For 
this reason the researchers have wanted to investigate on how this compound, 
when it is administered or taken, exerts a lot of healthy effects and a little of 
collateral effects. 
Cannabidiol has anti-oxidant, anti-inflammatory and  immunomodulatory effects. 
Moreover this substance is known to inhibit cancer cell invasion, angiogenesis 
and to decrease the growth of breast carcinoma and lung metastasis. This 
molecule activates cannabinoid receptors indirectly or rather it enhances levels of 
endocannabinoids, for example 2-arachidonoyglycerol in colorectal carcinoma 
cells and this action is chemopreventive.   
Furthermore it has been discovered that cannabidiol inhibits the cellular uptake 
and enzymatic hydrolysis of the endogenous cannabinoid anandamide, which is 
involved in pain control through activation of  CB1 and CB2 receptors; 
cannabidiol behaves as agonist of TRPV1, but we can not say whether it 
activates vanilloid receptors directly or indirectly, through anandamide (TRPV1 
receptors are up-regulated after inflammation and nerve injury and this may 
contribute to inflammatory and neuropathic hyperalgesia, so the therapeutic 
action of cannabidiol could be due to desensitization of this receptor, similarly to 
the natural agonist (capsaicin)).7,8,9  
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Biosynthesis of the Cannabinoids 
In all biosynthetic pathways for cannabinoids that were postulated until 1964, 
CBD or cannabidiolic acid (CBDA) was regarded as the key intermediate, which 
was supposedly built from a monoterpene and olivetol or olivetolic acid (OA), 
respectively. However, cannabigerol (CBG) is the common precursor of 
cannabinoids, biosynthesized through the condensation of geranyldiphosphate 
(GPP) and olivetol or OA. Subsequently, they concluded that CBD, THC, and 
cannabinol (CBN) all derive from CBG and differ mainly in the way this 
precursor is cyclized. It is today known that cannabinoids are produced by the 
metabolism of the plant in the form of carboxylic acids, where the substituent at 
position 2 is a carboxyl group (–COOH). The first specific biosynthetic step is 
the condensation of GPP with OA into cannabigerol acid (CBGA), catalyzed by 
the prenylase enzyme geranyldiphosphate: olivetolate-geranyltransferase (GOT). 
Furthermore, biosynthetic pathways finally became clear by identification and 
subsequent cloning of the genes responsible for the conversion of CBGA to 
THCA, CBDA, and cannabichromenic acid (CBCA), respectively. The terpenoid 
GPP derived from the deoxyxylulose phosphate/methyl-erythritol phosphate 
(DOXP/ MEP) pathway. Not much is known about the biosynthesis of OA yet, 
but it has been proposed that a polyketide synthase (PKS) could be involved 
(Figure 5).4  
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Figure 5. General overview of the biosynthesis of cannabinoids and putative routes.4 
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The Cannabinoid Receptors: CB1 and CB2 
The cannabinoid receptors are a class of receptors under the G-protein-coupled 
receptor superfamily. Cannabinoid receptors have a protein structure defined by 
an array of seven transmembrane-spanning helices with intervening intracellular 
loops and a C-terminal domain that can associate with G proteins of the Gi/o 
family (Figure 6). Their ligands are known as cannabinoids or endocannabinoids 
depending on whether they come from external or internal (endogenous) sources. 
Until the discovery of specific Cannabis receptors, the biochemical mode of 
action of cannabinoids was much debated. The cannabinoids have a lipophilic 
character and so they have a high possibility to penetrate cellular membranes by 
simple diffusion. Therefore, possible explanations for cannabinoid activity 
initially included unspecific membrane binding and it causes an increase in 
fluidity and permeability of neural membranes, inhibition of acetylcholine 
synthesis, a rise in the synthesis of catecholamines, and an interaction with the 
synaptosomal uptake of serotonin. However, it was established in the middle 
1980s that cannabinoid activity is highly stereoselective, indicating the existence 
of a receptor-mediated mechanism.  
The first reliable indications that cannabinoids act through receptors came when 
it was shown that cannabinoids can act as inhibitors of the adenylate cyclase 
second messenger pathway in brain tissue and neuroblastoma cell lines. This 
activity was dose-dependent and stereospecific. Finally, a stereospecific G-
protein-coupled cannabinoid receptor was found and cloned. It was named 
‘cannabinoid-binding receptor type 1’ or CB1R. The CB1 receptor is most 
clearly localized in the central nervous system (CNS), therefore it is often called 
the ‘central receptor’, but it is also found in certain peripheral organs and tissues, 
such as lungs, liver, and kidneys. CB1 receptors are thought to be the most 
widely expressed G-protein-coupled receptors in the brain. Activation leads to 
the inhibition of adenylate cyclase activity. The CB1 receptor also modulates ion 
channels, inducing, for example, the inhibition of N- and P/Q- type voltage-
sensitive Ca2+ channels and the activation of G-protein inwardly rectifying K+ 
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channels. The cannabinoid receptors have also  shown to modulate several 
signaling pathways that are more directly involved in the control of cell 
proliferation and survival, including extracellular signal-regulated kinase (ERK), 
c-jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase 
(MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, focal adhesion kinase 
(FAK), and the ceramide pathway. Subsequently, a second cannabinoid receptor 
(CB2R) was found with a possible role in immunological processes. The CB2 
receptor was first described as a peripheral G-protein-coupled receptor (GPCR), 
mainly localized in the immune system, therefore it is often called the ‘peripheral 
receptor’. However, nowadays it is well know that CB2R expression is hight in 
neurons of the brain too. It is important to underline that CB2R is primarily 
expressed by immune tissues such as leukocytes, spleen, and tonsils, and it 
shows a different selectivity than the centrally acting CB1R. So far, the 
physiological roles of CB2 receptors are proving more difficult to establish, but 
at least one seems to be the modulation of cytokine release. Recently, it has been 
recognized that CB2R may play a functionally relevant role in the CNS, 
mediated through microglial cells. It’s important to say the protein sequences of 
CB1R and CB2R show only about 45% homology.4 However, not all of the 
effects of cannabinoids can be explained by receptor-mediated effects, and it is 
believed that at least some effects are nonspecific and caused through membrane 
perturbation.10 
 
 
 
 
 
Figure 6. CB1 and CB2 receptors structures (Dizionario di Medicina, 2010, Treccani).
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The Endocannabinoid System 
Based on the observation that all natural cannabinoids are highly lipid-soluble, an 
attempt was made to isolate endogenous ligands for the cannabinoid receptors from 
fatty tissues of animals. Finally, a single compound could be isolated from the brain 
tissue of pigs and it has a high affinity for the CB1 receptor. It was chemically 
identified as arachidonic acid ethanolamide, and named anandamide (AEA). A few 
years later, a related compound was isolated from canine gut with an affinity for both 
cannabinoid receptors: 2-arachidonylglycerol (2-AG). Structures of these two 
compounds are shown in Figure 7. In recent years, a variety of compounds with 
endocannabinoid activity have been isolated or synthesized, interestingly, all having 
an eicosanoid-related structure. 
 
 
 
 
 
Figure 7. Structures of the two major endocannabinoids.4 
 
Discovery of cannabinoid receptors and their endogenous ligands allowed to the 
identification of a ubiquitous neuromodulatory system called endocannabinoid 
system.  
It consists of cannabinoid receptors, endogenous cannabinoids, and enzymes 
responsible for their production, transport, and degradation. The endocannabinoid 
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system can be found even in very primitive organisms, indicating it has a fundamental 
role in basic physiology. There are currently two main families of endocannabinoids 
that have been extensively characterized. The first are amides of arachidonic acid and 
ethanolamide; the typical example of this family is anandamide. The second family 
includes glycerol esters related to 2-AG. The biosynthetic pathways for both families 
of endocannabinoids are complex. There are several pathways known for the 
synthesis and degradation of endocannabinoids. Basically, endocannabinoids exist 
intracellularly as precursors in the plasma membrane of neurons as part of certain 
phospholipids. They are produced on demand by distinct biochemical pathways 
involving phospholipases C and D, as well as other enzymes. These events are 
triggered by the enhancement of intracellular calcium concentrations that causes cell 
depolarization or the mobilization of intracellular calcium stores subsequent to the 
stimulation of protein-coupled receptors from the Gq/G11 family (Figure 8).  
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Figure 8. An overview of the eCB signalling system in neuronal migration. DAGL-dependent local 
synthesis of 2-AG, the main eCB in the brain, can occur downstream of tyrosine kinase receptors 
(such as FGF and TrkB). Cell adhesion molecules (N-cadherin/NCAM) can also cross-talk with the 
FGF receptor. Following release of 2-AG (or after binding of other eCBs like anandamide), CB 
receptor activation can trigger stimulation of PI3K and MAPK pathways and activation of small 
GTPases such as Rap1, Rac and Rho, potentially regulating migration by affecting translation, 
adhesion and cytoskeletal rearrangement (Zhou Y. et al., The International Journal of Biochemistry 
& Cell Biology, 47, (2014), pp.104-108). 
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Accordingly, the enzymes catalyzing anandamide and 2-AG are calcium-sensitive. 
After formation, endocannabinoids are transported, across the cell membrane for 
interaction with their extracellular binding sites, on cannabinoid receptor (Figure 9).
 
 
 
 
 
 
 
 
 
Figure 9. Postsynaptic activity (e.g. Ca2+ influx through voltage-gated Ca2+ channels, VGCCs) 
along with metabotropic receptor activation (e.g. mGluR and mAChR), (Younts T.J., Castillo P. E., 
Current Opinion in Neurobiology, 26, (2014), pp.42-50). 
Endocannabinoids differ from other neurotransmitters such as acetylcholine, gamma-
aminobutyric acid (GABA) and dopamine since they most commonly travel backward 
against the usual synaptic transmitter flow. In fact, endocannabinoid signaling appears 
to occur via a retrograde mechanism: stimulation of the postsynaptic neuron triggers 
the biosynthesis of endocannabinoids, which are rekeased and transported to the 
presynaptic cell, where the target receptors are densely concentrated. The 
endocannabinoids exert a homeostatic function. Because of their chemical (non water-
soluble) nature, they cannot travel unaided for long distances in the aqueous medium 
 
 
21 
 
surrounding the cells from which they are released. Therefore, endocannabinoids do 
not typically function like hormones, they act as local (autocrine or paracrine) 
mediators. Activation of the cannabinoid receptors temporarily reduces the amount of 
conventional neurotransmitter released, since CBRs activation of G proteins initiates a 
signaling cascade that the inhibits the activity of voltage-gated calcium channels, thus 
reducing entry of Ca2+, and thereby forbidding the exocytosis of secretory vesicles. 
The ultimate outcome of cannabinoid signaling depends on the nature of the 
participating cells: endocannabinoid signaling will be inhibitory, if CB receptors are 
activated on glutamatergic neurons, whereas the net result will be disinhibitory (or 
excitatory) if CBRs activation takes a place on GABAergic neurons.  
When the local action of endocannabinoids has not neuron like target, but glial cells 
and microglia, stimulation of CB1R and primarily CB2R regulates many important 
functions, such as migration and activation, the release of pro- and anti-inflammatory 
cytokines and the ability of adjusting the neurotransmission by the release of 
neurotransmitters or seizure.  
Degradation is an important mechanism to regulate endocannabinoid activity, as the 
duration of endocannabinoid effect is dependent on the localization of the degrading 
enzymes. The degradation system involves reuptake into the presynaptic cell, 
followed by rapid hydrolysis of the amide or ester bonds. We do not know how 
endocannabinoids move from the extracellular space to the interior of a cell, but we 
have understood that they utilise specific proteins for faciliting the membrane 
transport. It has been discovered that 2-AG exhibits higher selectivity and efficacy for 
CB1 and CB2 receptors than anandamide, which also interacts with noncannabinoid 
receptor targets. Therefore the levels of the two compounds are regulated in different 
ways. However, the main enzyme that inactivates both anandamide and 2-AG (and 
others) by hydrolysis is fatty acid amide hydrolase (FAAH). 2-AG is also inactivated 
by monoacylglycerol lipase (MAGL) (Figure 10).4 
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Figure 10. Endocannabinoid synthesis and degradation pathways (D’Addario C. et al., Neuroscience 
& Biobehavioral Reviews, 47, (2014), pp. 203-224. 
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From Endocannabinoid System to “Endocannabinoidome” 
The endocannabinoid (eCB) system consists of receptors, endogenous ligands, 
and ligand metabolic enzymes. Metaphorically the eCB system represents a 
microcosm of psychoneuroimmunology or mind-body medicine. Cannabinoid 
receptor 1 (CB1R) is the most abundant G protein-coupled receptor expressed in 
the brain, but it is also expressed in non-neuronal cells, such as adipocytes and 
hepatocytes, and in musculoskeletal tissues. Cannabinoid receptor 2 (CB2R) is 
principally associated with cells governing immune function, although it may 
also be expressed in the central nervous system.  
The eCB ligands are anandamide (AEA) and 2-arachidonoylglycerol (2-AG). 
AEA is biosynthesized by N-acyl-phosphatidylethanolamine phospholipase D 
(NAPE-PLD) and 2-AG by two isoforms of diacylglycerol lipase, DAGLα and 
DAGLβ. After that these compounds have conducted their function, they are 
catabolized, AEA by FAAH1 and 2-AG by MAGL. 
In the last years this system has undergone to an expansion, because there has 
been the discovery of secondary receptors, ligands, and ligand metabolic 
enzymes. For example, AEA, 2-AG, N-arachidonoyl glycine (NAGly) and the 
phytocannabinoids Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) 
may also serve, to different extents, as ligands at GPR55, GPR18, GPR119, and 
several transient receptor potential ion channels (TRPV1, TRPV2, TRPA1, 
TRPM8). 
Moreover one of the most meaningful discoveries has been that the effects of 
AEA and 2-AG can be enhanced by ‘‘entourage compounds’’ that inhibit their 
hydrolysis via substrate competition, and thereby prolong their action. Entourage 
compounds include N-palmitylethanolamide (PEA), N-oleoylethanolamide 
(SEA), and cis-9-octadecenoamide (OEA, oleamide).11  
Particularly with regard to anandamide, the researchers have studied its uptake 
and the involved subjects in this action. Recent studies have identified 
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intracellular transport proteins (fatty acid binding proteins 5 and 7, heat shock 
protein 70, albumin, and fatty acid amide hydrolase-like AEA transporter 
protein) that shuttle AEA from the plasma membrane to its metabolic enzymes. 
The anandamide needs of a carrier for crossing the plasma membrane, but it is 
unclear why a lipophilic molecule such as AEA would need ‘help’. 
It is thought that an FAAH-driven AEA uptake can be generalised. A lot of 
intracellular AEA carrier proteins have been proposed and given that AEA 
carriers must be ubiquitous and able to bind lipophilic compounds, the scientists 
have indentified fatty acid binding proteins (FABPs).   
Most recently studies have underlined the identification of a variant of FAAH 
that was catalytically inactive, but which bound AEA, it was FLAT (FAAH-like 
anandamide transporter). This carrier lacks the membrane-anchoring domain of 
the FAAH dimer. FLAT is an important protein, that transports anandamide in 
cells, where it will be destroyed, but this protein does not degrade it.  It has been 
proved taht in mouse brain neurons, genetic deletion of FAAH (which eliminates 
both FAAH and FLAT) reduces but does not eliminate AEA uptake (Figure 11). 
 
 
 
 
 
 
 
 
Figure 11. Conceptualised uptake and metabolism of anandamide (AEA) in a model, which 
does not invoke the presence of a plasma-membrane transporter protein.12 
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Furthermore a recent study has spoken about the transient receptor potential 
vanilloid 1 (TRPV1), a receptor, which behaves like a biosensor to measure the 
intracellular accumulation of AEA, but about this the knowledges are still little. 
The ongoing studies are based on three areas: 
1) Uptake versus endocytosis of AEA, because there is evidence that AEA 
can be internalised by endocytotic processes, although some of the 
compounds used to disrupt endocytosis are far from selective. Further 
research is necessary to determine whether cells use both endocytotic and 
transmembrane mechanisms of AEA uptake or other processes;  
2) Uptake of 2-AG, which has been identified as the endocannabinoid 
primarily involved in many retrograde signalling processes. In this case, 
both the target CB1 receptors and the main metabolic enzyme for 2-AG 
are located presynaptically and a plasma-membrane transporter would be 
expected to compete with the receptor for 2-AG. This may be an elegant 
way of regulating the degree of retrograde signalling, or alternatively an 
argument against a membrane transporter. 
3) Balance of intracellular carriers and metabolic enzymes in pathological 
conditions: ischaemia, for example, changes hippocampal expression of 
FABP5, FABP7 and Hsp70. Cytokines can affect FAAH expression, so it 
is not inconceivable that FLAT expression might also be affected. 
Changes in these characteristics modify the accumulation and metabolism 
of AEA and in this way  novel possibilities for therapeutic intervention is 
created.12  
However, endocannabinoids and AEA in particular, may interact with other 
targets besides to “classic targets” and produce other positive effects, for 
example in case of TRPV1 activation, pro-nociceptive effects.  
Moreover, the existence of multiple endocannabinoid-degradation pathways 
allows the realization of new inhibitors and in this way an enhancement of 
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endocannabinoid levels is caused, besides this the presence of other receptors, 
definied “orphan receptor”, involved in endocannabinoid system, gives to the 
researcher a new possibility of using them like new targets. Naturally, as above 
described, the new pharmacologic opportunities, that “Endocannabinoidome” 
offers, are a lot. Consequetly, considering that a multi-target approach has been 
reached, a polypharmacology treatment has been obtained and so the 
effectiveness of therapy has been increased.13  
 
 
27 
 
Role of CB1R and CB2R in Neuroprotection 
The CB1 and CB2 receptors have widely been associated with neuroprotection. 
The most extensively studied mechanism of neuroprotection includes the 
antinflammatory effects of the CB2 receptor. In contrast, the CB1 receptor has 
been implicated in protection against cell death induced by an overstimulation of 
excitatory receptors and concurrent calcium release, also known as 
excitotoxicity. In like manner, cannabinoid receptor ligands are often reported to 
be antioxidative.14  
It is well known that CB1R and CB2R activities are strictly linked to their 
respectively localization. In fact, most of physiological functions associated with 
the CB2 receptor deal with different types of immunological effects given the 
predominance of this receptor type in immune tissues. However, its recent 
description in certain brain regions allows us to relate different neurobiological 
processes, for example control of pain, brain reward, emotion and others to CB2 
receptor activity.15 Interestingly is the implication of the CB2 receptor in 
processes related to the control of proliferation16, differentiation17 and survival18 
of neural cells. The CB2 receptor plays an important role in this process because 
it provides cytoprotection of healthy neural cells or apoptosis of tumoral cells. 
The former property, more than the lattest, is related to CB2 receptor capability 
to arrest/delay brain damage in different neurodegenerative disorders, 
particularly in those that exhibit an important local inflammatory component 
associated with brain injury. Also CB1 receptor is involved in neuroprotection 
mechanism since it is associated with inhibition of glutamate release, decrease of 
cytosolic free Ca2+ concentration and vasodilation, effects that are overall 
capable to increase neuronal survival.19 This potential, together with other 
cannabinoid receptor-independent properties allows cannabinoids to protect 
neurons from death (cerebral ischemia and trauma) and from chronic 
neurodegenerative disorders ( Alzheimer’s disease (AD), Parkinson’s disease 
(PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)).
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Role of CB1R and CB2R in Neuropathogenesis 
CB1 and CB2 receptors have been implicated in a number of neuropathogenic 
processes. However, the cannabinoid receptor type correlated to an inflammatory 
response within the CNS appears to be CB2R. Microglia apparently act as the major 
expressers of this receptor during early stages of neuroinflammation. In the CNS 
resident macrophages migrate and proliferate during and after injury and 
inflammation, phagocytose and process antigens, and once activated produce pro- 
inflammatory factors including the cytokines interleukin (IL)-1, IL-6, and tumor 
necrosis factor (TNF) α. Pro-inflammatory mediators released from microglia not 
only are exocytotoxic, but also can secondarily activate astrocytes leading to a further 
induction of the expression of inflammatory factors. Paradoxically, microglia not only 
play a role in host defense and tissue repair in the CNS, but also have been implicated 
as contributing to nervous system disorders such as Mutiple Sclerosis (MS). This 
deleterious role of microglia is exacerbated by inflammatory factors that are elicited 
from microglia and astrocytes contribute to breakdown of the Blood Brain Barrier 
(BBB) and play a critical role in the influx into the CNS of immunocytes from 
peripheral non-neuronal sites that also express CB2R. In vitro and in vivo studies have 
shown that cannabinoids can act on glia and neurons to inhibit the release of pro-
inflammatory cytokines and enhance the release of anti-inflammatory factors such as 
the cytokines IL-4 and IL-10. These observations suggest that these cannabinoids, as 
lipophilic molecules, can readily access the CNS and have the potential to ablate a 
variety of neuropathological processes that are associated with pro-inflammatory 
states. There are also evidences that expression of CB2 receptor is up-regulated in 
vitro by microglia and other immune cells in response to immune modulators and in 
vivo during states of chronic neuroinflammation. Thus, using CB2-selective agonists 
it may be possible to target specific cell types such as microglia that are associated 
with inflammatory processes in the brain.20  
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Alzheimer’s disease (AD) 
AD is the most common neurodegenerative disorder that causes senile dementia. The 
series of events that leads to AD is poorly understood and insights into its 
pathogenesis have been obtained primarily from assessment of human brain tissue at 
autopsy. Neurodegeneration in AD is caused by effects, that multiple neurotransmitter 
systems induces, including those of specific cholinergic, noradrenergic, serotonergeic, 
GABAergic, and glutamatergic neurons. The defining neuropathologic features of the 
disease are the presence of extracellular neuritic amyloid plaques and intracellular 
neurofibrillary tangles (NFTs) in the brain. This characteristic is accompanied by 
synaptic and neuronal loss and gliosis in the cerebral cortex and the limbic system. 
The amyloid plaques consist of extracellular aggregates of amyloid β (Aβ) peptides 
that often are surrounded by activated microglia and astrocytes. The NFTs consist of 
intraneuronal aggregates of paired-helical filaments that usually are composed of 
hyperphosphorylated microtubule-associated protein tau (Figure 12). As 
neurodegeneration progresses there is accelerated neurofibrillary tangle formation, 
neuroinflammation, and neuronal loss. Alterations in components of the cannabinoid 
system have been observed in brains of Alzheimer’s patients, suggesting that this 
system contributes to, or is altered by, the disease. It was suggested that the losses in 
cannabinoid receptors, while related to generalized aging and/or the disease process, 
were not selectively associated with the pathology characteristic of AD. On the other 
hand, CB2R and FAAH have been reported to be selectively over-expressed in 
neuritic plaque associated glia in AD brains.  
Immunohistochemical staining of hippocampus and entorhinal cortex sections 
demonstrated that both FAAH and CB2R were abundantly and selectively expressed 
in neuritic plaque associated astrocytes and microglia. Intracerebroventricular 
administration of the cannabinoid receptor agonist WIN55212-2 prevented Aβ-
induced activation of microglia, cognitive impairment, and loss of neuronal markers. 
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In addition, treatment of microglia in vitro with WIN55212-2, and two other CBR 
agonists, HU-210 and JWH-133 resulted in blockage of their activation by Aβ peptide 
and abrogated neurotoxicity mediated by these cells. These results indicate that WIN-
55212-2 exerted anti-inflammatory properties in a model of chronic brain 
inflammation produced by infusion of bacterial lipopolysaccharide (LPS) into the 
fourth ventricle of young rats. It was suggested that WIN-55212-2 exerted an indirect 
effect on activation of microglia and impairment of memory. On the other hand, it has 
been reported that stimulation of CB2R results in suppression of inflammatory 
mediators such as NO, cytokines, and chemokines that play a role in microglial cell-
associated neuronal damage.20  
 
 
 
 
 
 
 
 
 
 
Figure 12. Immagine of neuron in normal subject, mild cognitive impairment and profound dementia 
(Faghihi M.A. et al., Neuroscience Letters, 466, (2009), pp.81-88). 
 
 
31 
 
Multiple Sclerosis (MS) 
MS is also known as “disseminated sclerosis” or “encephalomyelitis disseminate”. It 
is a chronic, inflammatory demyelinating disease of the human CNS that primarily 
affects adults. This pathology causes muscle weakness, abnormal muscle spasms, 
changes in sensation,  difficulty with coordination and balance, cognitive impairment, 
problems with speech, swallowing and sight. The disease is characterized by 
degeneration of the myelin sheath that covers axons, in which T cells play a 
prominent role. These cells attack myelin with the resulting inflammatory process and 
so other immune cells are stimulated to produce soluble factors such as cytokines and 
antibodies. The inflammatory process results in breakdown of the BBB leading to 
swelling, activation of macrophages and further production of cytokines and 
“cytotoxic” proteins such as metalloproteinases. Remyelination may occur in the early 
phase of the disease and it could be an opportunity for healing, but the 
oligodendrocytes that originally formed the myelin sheath cannot completely rebuild 
the destroyed myelin. 
Thanks to several experiments, it is well understod that demyelination in the CNS is 
due to migration of activated myelin-specific T lymphocytes across the tight 
endothelial junctions that comprise the BBB and from the elaboration of chemokines 
and cytokines by these T lymphocytes. The resultant influx of peripheral mononuclear 
phagocytes into the CNS leads to progressive hind- limb paralysis.21 
Most studies, with aim for discovering the effects of cannabinoids on MS have 
involved the use of the mouse EAE model (mouse with Experimental Autoimmune 
Encephalomyelitis) and it is caused by Theiler’s murine encephalomyelitis virus, that 
induces  demyelinating disease (TMEV-IDD). Mouse deficient in CB1R have been 
shown to tolerate inflammatory and excitotoxic insults poorly and to develop 
substantial neurodegeneration following immune attack.22 Afterwards with these 
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observations, THC has been reported to markedly inhibit neurodegeneration in the 
EAE model and to reduce the associated induced elevated level of glutamate in 
cerebrospinal fluid. Glutamate, the major excitatory neurotransmitter in the cerebral 
cortex, has been implicated in neurodegenerative disease, because it is present at high 
levels. About this, the scientists have observed that the use of the CB1R antagonist 
(SR141716A) caused the inhibition of glutamate release and so they have understood 
that the granting of the neurotransmitter was activated by CB1 receptor. Further 
support for a role of the CB1R in moderating MS in experimental animals has been 
obtained from studies using CB1R knockout mice. These animals have shown many 
damages thus all the data suggested that signaling through CB1R conferred 
neuroprotection during EAE. The CB1 receptor exhibited down-regulatory responses 
that were circumscribed to motor-related regions that, generally, were more marked 
during the acute and chronic phases of disease. It was suggested that these 
observations explained the efficacy of cannabinoid agonists in improving motor 
symptoms such as spasticity, tremor, and ataxia that are typical of MS in humans and 
in animal models. Control of spasticity in the MS model as mediated by CB1R and 
not CB2R also has been suggested through studies in which spasticity was induced in 
wild type and CB1R-deficient mice following the development of relapsing EAE. 
CB2-selective agonists such as RWJ400065 did not inhibit spasticity. The anti-spastic 
activity of RWJ400065 and the therapeutic effect of the non-selective CB1R/CB2R 
agonists WIN55212-2 and CP55940 were lost in spastic, CB1R-deficient mice. It 
shows that it is not sufficient the presence of CB2R, but it is strictly necessary that of 
CB1R. 
After it has been seen that EAE rats also have been reported to exhibit changes in 
endocannabinoid levels. Levels of anandamide and 2-AG were decreased in motor 
related regions such as the striatum and midbrain as well as in other brain regions.  
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The role of cannabinoids in neuroprotection in mouse and rat EAE models has been 
confirmed using the TMEV-IDD model. Using this animal model, treatment with 
WIN 55212-2, ACEA (a selective CB1R agonist) and JWH-015 (a selective CB2R 
agonist) during established disease resulted in ablation of neurological deficits. These 
cannabinoids reduced microglial activation, abrogated Major Histocompatibility 
Complex (MHC) class II antigen expression, and decreased the number of CD4+ 
infiltrating T cells into the spinal cord. WIN55212 causes an improvement in the 
progression of symptoms of clinical disease in mice with pre-existing TMEV-IDD. 
WIN 55212-2 also has been found to attenuate the increase in leukocyte rolling and 
endothelial adhesion in the brain that is associated with EAE. Subsequently, using 
CB1R (SR 141716A) and CB2R (SR144528) antagonists it was demonstrated that the 
cannabinoid-mediated inhibitory effects on leukocyte/endothelial interactions were 
through CB2R. Another important discovery was that WIN 55212-2 has been 
demonstrated to increase cyclooxygenase-2 (COX-2) expression and prostaglandin-
E2 (PGE2) release in endothelial cells. Treatment with WIN 55212-2 resulted in up- 
regulation of COX-2 protein and PGE2 release that was attributed to a mechanism 
independent of activation of CB1R or CB2R. 
More recent studies indicate that neuroprotective effects of cannabinoids can be 
exerted through activation of both CB1R and CB2R.  
The role of ‘indirect’ agonists, compounds able to reinforce physiological 
endocannabinoid transmission and devoid of psychotropic effects has been examined 
in ameliorating neurological deficits due to MS. Using the TMEV-IDD model, it was 
demonstrated that treatment with the selective anandamide uptake inhibitor UCM707 
during established disease resulted in significant improvement in motor function. 
UCM707 was able to reduce microglial activation, diminish MHC class II antigen 
expression, decrease cellular infiltrates in the spinal cord, and decrease the production 
of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. It has been reported also 
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that the endocannabinoid system is highly activated during CNS inflammation and 
that anandamide protects neurons from inflammatory damage through a CB1R/CB2R-
mediated rapid induction of microglial mitogen-activated protein kinase phosphatase-
1 (mkp-1) that is associated with histone H3 phoshorylation of the mkp-1 gene 
sequence. It was suggested that anandamide induced a rapid mkp-1 switch off of 
MAPK signal transduction that was activated by stimulation of pattern recognition 
receptors. It was proposed that the release of anandamide served as a mode of 
neuroimmune communication that could control and limit the immune response after 
primary CNS injury (Figure 13).20 
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Figure 13. The complex role of the cannabinoid system and possible therapeutic targets in MS-
induced inflammation. Cannabinoids may combat inflammation by modulating cytokines, 
inflammatory mediators, T cell proliferation and effector function, B cell antigen presentation and 
activation of microglia and astrocytes. Moreover,they may limit the ability of leukocytes to cross the 
BBB and enter the brain by inhibition of molecules implicated in leukocyte endothelium trafficking.14
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Amyotrophic Lateral Sclerosis (ASL) 
ALS is a chronic neuromuscular disease that is characterized pathologically by 
progressive degeneration of cortical motor neurons (upper motor neurons) and 
clinically by muscle wasting, weakness, and spasticity that progresses to complete 
paralysis. This adult-onset disease occurs in both sporadic and familial forms. The 
familial ALS (FALS) form is inherited as an autosomal dominant trait and accounts 
for 5% to 10% of cases of ALS. FALS has been linked to mutations in the superoxide 
dismutase 1 (SOD1) gene that codes for a zinc and copper binding enzyme which 
neutralizes supercharged oxygen molecule (superoxide radical) by products of normal 
cellular metabolism. One mode involved in ALS pathology is neuroinflammmation, 
that is mediated by pro-inflammatory cytokines, prostaglandins, and nitric oxide 
(NO). More recently in the experiment with mice, it has been shown that the CB2 
agonist AM-1241 has been reported as contributing to prolonged survival of SOD1 
mutant mice. In addition, treatment with non-selective cannabinoid partial agonists 
prior to, or upon, the appearance of symptoms of ALS was shown to delay disease 
progression and promote prolonged survival of mice.  
It has been demonstrated also that levels of endocannabinoids are affected in 
experimental ALS. The amount of anandamide and 2-AG, endocannabinoids that 
have been implicated in playing a neuroprotective role, increased in the spinal cord of 
SOD1 transgenic mice. Anandamide and 2-AG not only are upregulated with disease 
progression, but also postsymptomatic treatment with WIN55212 resulted in a delay 
in disease progression.20  
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Role of CB1R and CB2R in Cancer 
Cannabinoids have been successfully used in the treatment of some of the side effects, 
such as nausea and vomiting, weight loss, lack of appetite and pain that often 
accompany cancer. In fact, Marinol and Cesamet (oral capsules of nabilone – a 
synthetic THC analogue) can be prescribed to prevent nausea and vomiting elicited by 
standard chemotherapeutic regimes. Although cannabinoids are used in the palliative 
treatment of cancer, for example Sativex is approved in Canada for the treatment of 
cancer-associated pain.  
Unfortunately they are not yet used as a treatment for tumor progression it-self. 
However, aside from these palliative actions, recent preclinical evidence suggests that 
cancer patients might benefit from cannabinoids in an additional manner. It has been 
demonstrated that administration of Δ9-THC, Δ8-THC and cannabinol inhibited the 
growth of Lewis lung adenocarcinoma cell growth in vitro and in vivo after oral 
administration to mouse. Since then, cannabinoids have been shown to have anti-
proliferative, anti-metastatic, anti-angiogenic and pro-apoptotic effects in various 
cancer types (lung, glioma, thyroid, lymphoma, skin, pancreas, uterus, breast and 
prostate carcinoma) using both in vitro and in vivo models.23,24 Recently, more 
evidences have been obtained that suggest that phyto-, endo- and syn- thetic 
cannabinoids could be useful in the treatment of cancer due to their ability to regulate 
cellular signaling pathways critical for cell growth and survival.25,26  
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Role of CB1R and CB2R in Pain 
Pain has a negative impact on the life quality in cancer patients. Almost half of all 
patients with cancer experience moderate to severe pain, and this increases in patients 
with metastatic or advanced stages of cancer. This burden negatively affects their life 
quality, functional status and life expectancy. Cancer pain is often treated with opioid 
drugs (codeine, morphine, and/or their synthetic analogues); however, these drugs 
have dose-limiting side-effects. The use of cannabinoids to treat cancer pain may 
provide a novel therapeutic approach, because they have the capability to inhibit pain 
transmission. Cannabinoids are excellent analgesics in acute pain and chronic pain. 
Cannabinoids modulate nociceptive processing, because they work at the level of 
central and peripheral mechanisms. The majority of these effects are mediated by CB1 
receptors located in both areas, but although CB2 receptors were detected in the 
nervous system in much lower levels than CB1 receptors. Recent experiments have 
demonstred that CB2R-selective ligands are more active in animal models with 
hyperalgesia. 
The analgesic effect of cannabinoids is attributed in particular to activation of these 
receptors in the brain, the spinal cord and nerve terminals. 
Health Canada approved Sativex in 2007, with conditions, as adjunctive analgesic 
treatment in adult patients with advanced cancer who experience moderate to severe 
pain during the highest tolerated dose of strong opioid therapy for persistent 
background pain.27,28 
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Cannabinoid Receptor Ligands 
Cannabinoid receptor agonists and antagonists were reviewed in several studies 
(Figure 14). 29,30 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Schematic of G protein coupled receptor (GPCR).  
Panel A: illustration of inactive receptor (left) and agonist-activated receptor (right). In the inactive 
state, the G protein–GDP bound subunit complex is bound to the receptor protein (left); whereas 
upon binding of agonist at the orthosteric site, the receptor is activated and the G protein subunits βγ 
dissociate from the GTP bound α subunit (right). Panel B illustrates binding of either competitive 
antagonist or negative allosteric modulator at orthosteric and allosteric sites respec- tively. Note that 
the receptor is not activated by either of these ligands. Panel C: binding of a positive allosteric 
modulator, at an allosteric site. Note that this ligand does not activate the receptor in and of itself. 
Panel D: constitutive activity is demonstrated on the left. The receptor is in an activated state, bound 
to the α subunit of the GDP–G protein complex, in the absence of agonist. Presumably in this state 
the receptor conformation is different from the agonist-receptor conformation, indicated by a 
difference in receptor shape and shad- ing. Binding of an inverse agonist, at the orthosteric site of a 
constitutively active receptor causes a “deactivation” of constitutive activity, a presumed 
conformational change, and recoupling of the G-protein subunits with the receptor. Note that the 
position of the G protein complex is shown bound to the receptor in a slightly different location to 
illustrate a different G protein-receptor conformational state, accommodating decreased basal 
activity consequent to inverse agonist binding.31 
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Agonists 
A lot of potent agonists have been discovered and they can be subdivided into four 
groups according to their chemical structures. The first group (classical cannabinoids) 
is represented by dibenzopyran derivatives that are both natural constituents of 
cannabis (Δ9-THC and Δ8-THC) and their synthetic analogues (HU 210). The first 
generation of classical cannabinoids lacked CB1R/CB2R selectivity but they were 
developed by making relatively minor changes to the THC molecule (CB2R-selective 
agonists: JWH-133 and HU-308).32,33,34 The second group (non-classical 
cannabinoids) are the bicylic and tricyclic analogues of Δ9-THC lacking the pyran 
ring.35,36 This group includes the main cannabinoid agonist, CP55940, which binds to 
both CB1 and CB2 receptors with similar affinity and displays high activity in vivo. It 
is 10 to 50 times more potent than Δ9-THC in the mouse model.35 CP55940 behaves 
as a full agonist for both receptor types. The third group of cannabimimetic 
compounds contains the aminoalkylindoles. In these series, the most important is 
WIN 55212-2, which displays high affinity for both CB receptors, albeit with 
moderate selectivity in favour of the CB2 receptors. Some of these aminoalkylindoles 
have been found to display significant selectivity for the CB2R (JWH-015).37,38 The 
prototype of the fourth eicosanoid group, which involves arachidonic acid derivatives, 
is anandamide, the first endogenous cannabinoid isolated from mammalian brain.39 
Cannabinoid agonists such as WIN55-212-2 and CP55-940 produce a characteristic 
combination of four prototypic profiles (response to the tetrad tests) including 
catalepsy, analgesia, hypoactivity and hypothermia.40 These effects are reversed by 
the selective CB1R antagonist SR141716A (rimonabant), providing evidence for the 
involvement of CB1R-related mechanisms.41 Although, many cannabinoid receptor 
ligands show only little or modest selectivity for both CBRs, a number of synthetic 
compounds are known to have significant selectivity for the CB2 receptors.42 CB2R-
selective agonists lack psychoactivity effect and so CB2 receptors are considered to 
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be interesting targets for treating neurological disorders.43 
Some effects of cannabinoid receptor agonists show a biphasic behaviour that is 
dependent upon dose. For example, low doses of anandamide stimulated leukocyte 
phagocytosis and aggressive behavioural activities while high doses caused inhibitory 
effects on this immune function and decreased aggressiveness in mice.44 
 
 
 
 
 
 
 
Agonist of CB1R 
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Agonist of CB2R 
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Antagonists 
The first specific cannabinoid antagonist was SR141716A.42 It blocks the actions 
of various cannabinoid agonists in vivo. This compound is a pure antagonist at 
low (nanomolar) concentrations, with higher potency and selectivity for CB1 
than CB2 receptors. Even if SR141716A is CB1R-selective, it is not CB1R-
specific and it blocks both CB1 and CB2 receptors at sufficiently high doses.45  
When administered the above mentioned antagonists, with cannabinoid receptor 
they may behave as inverse agonists in several bioassay systems. This means that 
they not only block the effects of endocannabinoids but also produce effects that 
are opposite from those produced by cannabinoid receptor agonists and 
suggesting that the cannabinoid system is tonically active. This tonic activity 
may be due to a constant release of endocannabinoids or results from a portion of 
cannabinoid receptors existing in a constitutively active state.46  
Two analogues of SR141716A that have also been used to block CB1 receptor-
mediated effects are AM251 and AM281. On the other hand, AM630 is a CB2R-
selective antagonist/inverse agonist. It has been shown to potently reverse 
CP55940-induced inhibition.47 
Antagonist of CB1R 
 
 
 
 
 
 
 
 
44 
 
 
 
 
 
 
 
 
Antagonist of CB2R 
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Brief Introduction to the Endocannabinoid System 
Cannabis sativa L. (cannabis) is an annual dioecious plant belonging to the 
family Cannabaceae. Cannabis has a long history of human use as a medicinal 
plant, intoxicant, and ritual drug.1 Chemical analysis of this plant in the 1940s 
and 1960s have revealed the presence of a group of terpeno-phenolic metabolites, 
known as cannabinoids, of which trans-Δ9-tetrahydrocannabinol (Δ9-THC) and 
cannabidiol (CBD) are the best characterized.2  
In the early 1990s two G-protein coupled receptors were identified as clearly 
responsible for mediating Δ9-THC activity. Now these two receptors are known 
as cannabinoid receptors, type 1 (CB1R) and type 2 (CB2R). They have been 
cloned and characterized from mammalian tissues. CB1R is abundantly 
expressed in the central nervous system (CNS), but it is also localized outside the 
brain for example in liver, muscle, the gastrointestinal tract, heart, adrenal gland, 
testis, uterus and prostate. CB2R is mainly present in cells of immune system, 
but it has been found in low concentration in brain.48 Cannabinoid receptors and 
endocannabinoid ligands (anandamide and 2-arachidonoylglycerol), together 
with enzymes implicated in endocannabinoid biosynthesis, degradation (MAGL 
and FAAH) and transport constitute the endocannabinoid system (ECS).4 In the 
last years, this system has undergone to an expansion (“endocannabinoidome”) 
since secondary receptors, ligands, and ligand metabolic enzymes were 
individuated. Recently researchers have observed that the effects of the two 
principal endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-
AG), can be enhanced by ‘‘entourage compounds’’ that inhibit their hydrolysis 
Introduction to 
Experimental Part  
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via substrate competition, and thereby prolong their action. “Entourage 
compounds” include N-palmitylethanolamide (PEA), N-oleoylethanolamide 
(SEA), and cis-9-octadecenoamide (OEA, oleamide).11 Moreover, recently, EMT 
(Endocannabinoid Membrane Transporter) was discovered as the putative cell 
membrane transporter that controls the bidirectional movement of 2-AG and 
AEA across plasma membrane. Since indirect agonistic modulation of the 
endocannabinoid system provides a promising therapeutic strategy during several 
pathological conditions, potentiation of anandamide and 2-AG signaling trough 
inhibition of their cellular uptake could represent an innovative possibility.10  
The endocannabinoid system is involved in several physiological and 
pathological processes including cancer, appetite, fertility, memory, neuropathic 
and inflammatory pain, obesity, neuroprotection and neurodegenerative diseases 
for example Alzheimer’s disease, multiple sclerosis etc. For these reasons, the 
development of CBR ligands has attracted the interest of different research 
groups, which paid particular attention to the design of selective CB2R ligands, 
avoid of CB1R-mediated psychoactive effects.49 
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Structural Design 
Previously in a research program aimed at obtaining CB2R selective ligands, a 
series of 2-oxo-1,2-dihydropyridine-3-carboxamide derivates (compounds with 
general structure A, Figure 15) was developed in the laboratory, where I 
performed my thesis work. 50,51  
 
 
 
 
 
 
These compounds presented a p-fluorobenzyl or an ethylmorpholine moiety in 
position 1 and an alkyl amide in position 3 of the pyridine ring and they were 
non-substituted or substituted at position 5. 
Derivatives with general structure A showed potent and selective affinity towards 
CB2 receptors. Interestingly it was discovered that the substituent in position 5 of 
the pyridine ring was the main responsible for the functional activity of this class 
of compounds.51 In particular, replacing hydrogen or bromine atom in position 
C5 with a phenyl group and with a p-methoxyphenyl group, CB2R activity shifts 
from agonism to inverse agonism and neutral antagonism, respectively (Figure 
16). 
Figure 15. 2-oxo-1,2-dihydropyridine-3-carboxamide derivates A. 
R1 = ethylmorpholine, p-fluorobenzyl; 
R2 = 4-methylciclohexyl, cycloheptyl; 
R3 = phenyl, p-methoxyphenyl, p-fluorophenyl. 
A 
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After, in order to investigate the structure-activity relationship within this class of 
compounds, a series of 6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 
derivatives (compounds with general structure B, Figure 17) was developed by 
inserting a methyl group in position 6 of the 2-oxo-1,2-dihydropyridine ring to 
evaluate the influence of a small substituent in this position on CBR affinity. 
 
 
 
 
A B 
Figure 17. Design of compounds with general structure B. 
Figure 16. Substituent in position 5 is the main responsible for the functional activity of the 
class of 2-oxo-1,2-dihydropyridine-3-carboxamide derivatives. 
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Substituents in position 1 (R1 in Figure 18) and in position 5 (R3 in Figure 18) 
and aliphatic carboxamide in position 3 (R2 in Figure 18) of compounds with 
general structure B, have been chosen on the basis of the best results obtained for 
previous derivatives with general structure A. 
  
 
 
 
 
 
 
The insertion of a methyl group in position C6 does not significantly affet neither 
the binding of 2-oxopyridine-1,2-dihydropyridine-3-carboxamide derivatives A 
nor the influence of the substituent in C5 position on the functional modulation 
of CB2R. 
Coherently with these results, to further deepen the structure-activity relationship 
of this class of compounds, during my thesis work I modified the 2-oxo-1,2-
dihydropyridine-3-carboxamide nucleus following three different approaches: 
1) Shift of the methyl group of compounds B from 6 to 4 position of the 
pyridine ring to obtain 4-methyl-2-oxo-1,2-dihydropyridin-3-carboxamide 
derivatives C and D (Figure 19a). 
2) Shift of the aromatic substituents of compounds A from 5 to 4 position of 
the pyridine ring to obtain the correspondent 4-aryl-2-oxo-1,2-
Figure 18. 6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives B. 
R1 = p-fluorobenzyl, ethylmorpholine; 
R2 = cycloheptyl; 
R3 = H, Br, phenyl, p-methoxyphenyl. 
B 
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dihydropyridin-3-carboxamide derivatives E (Figure 19b). 
3) Insertion of a further substituent in position 4 of the pyridine ring of 
compounds A to obtain F derivatives (Figure 19c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. a) 4-methyl-2-oxo-1,2-dihydropyridin-3-carboxamide derivatives C and D; b) 6-
aryl-2-oxo-1,2-dihydropyridin-3-carboxamide derivatives E; c) derivatives with general 
structure F. 
 
 
51 
 
 
Thus, I designed and synthesized compounds with general structure C, D, E and 
F (Figure 20). 
 
 
 
 
 
 
All the substituents have been chosen on the basis of the best results obtained 
with the previous compounds. Therefore, all the synthesized compounds are 
characterized by the presence of a p-fluorobenzyl group in position 1 of the 
pyridine nucleus and a cycloheptyl moiety at the 3-carboxamide nitrogen. 
Moreover, hydrogen, bromine, phenyl and p-methoxyphenyl are the substituents 
chosen for the position 5 (R1), of compounds D and F whereas the phenyl and the 
the p-methoxyphenyl moieties characterized the position 4 of compounds E and 
F. 
 
Figure 20. Compounds with general sturctures C, D, E, and F. 
R1 = Br, phenyl, p-methoxyphenyl 
R2 = phenyl, p-methoxyphenyl 
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Reagents and conditions: (a) NH4OAc, AcOH, toluene, reflux, 116 °C, 8 h; (b) conc. 
H2SO4, 50 °C, 3 h; (c) 50% H2SO4, reflux, 120 °C, 8 h; (d) MeOH, conc. H2SO4., MW, 110 
°C, 50 min, (200 W, 100 psi) or reflux, 85 °C, overnight; (e) cycloheptylamine, MW, 130 
°C, 30 min, (140 W, 100 psi) or reflux, 150 °C, 48 h; (f) 1) CsF, dry DMF, 1h, r.t.; 2) 4-
fluorobenzyl chloride, r.t, overnight. 
Synthetic Chemistry 
Synthesis of 4-methyl-2-oxo-1,2-dihydropyridine derivatives 
The series of 4-methyl-2-oxo-1,2-dihydropyridine derivatives C and D (Figure 
19a) derived from the shifting of the methyl group of compounds B from 6 to 4 
position of the pyridine ring. 
Compounds with general structure C were prepared following the synthetic route 
shown in Scheme 1.  
 
 
 
Scheme 1. Synthetic procedure for compounds C. 
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The key compound of this synthetic route is 3-cyano-2-hydroxy-4-
methylpyridine 17. This derivative was obtained via a two-step procedure.3 
Firstly, a Knoevenagel condensation of 4,4-dimethoxyl-2-butanone 15 with 2-
cyanoacetamide 16, in presence of the mixture 4 wt% ammonium acetate/30 wt% 
acetic acid as catalyst and using anhydrous toluene as solvent, afforded 
intermediate I.  
The possible mechanism of the condensation of 15 with 16 is reported in Scheme 
2.52  
 
 
 
 
 
Since the mechanism of the condensation involves lose of water, an azeotropic 
distillation was adopted to remove it from the reaction environment. After, 
intermediate I, not isolated because of its high boiling point,52 was directly 
hydrolyzed to aldeide under acid conditions, and then condensed with the amino 
to afford 3-cyano-2-hydroxy-4-methyl-pyridine 17. This reaction was performed 
using concentrated H2SO4 and heating the mixture at 50° C for 3 h.52 Then 
compound 17 was then hydrolyzed to the corresponding carboxylic acid 
derivative 18 by heating at 120 °C with 50% H2SO4.53 The carboxylic acid 18 
was treated with concentrated H2SO4 and MeOH and heated at 100° C in a 
microwave reactor (CEM) for 50 minutes (200 W, 100 psi) 50 or refluxed at 85° 
C, overnight, to give the corresponding methyl ester 19, which was reacted with 
cycloheptylamine at 130 °C in a microwave reactor (CEM) for 30 minutes (140 
Scheme 2. Possible mechanism of the Knovenagel condensation of 15 with 16. 
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W, 100 psi) or under reflux at 150° C for 48 h to afford the carboxamide 
derivative 20.50 Finally, compound 20 was treated with CsF in anhydrous DMF, 
at 25 °C, and, after 1 h, added of p-fluorobenzyl chloride,54 giving the desired N-
alkylated derivative 1. 2-(p-fluorobenzyloxy)pyridine derivative 2 was also 
obtained, therefore separation by chromatography of the two positional isomers 
was necessary. The structure of compounds 1-2 was verified by 1H-NMR 
analysis. The two isomers was easly distinguished since the benzylic methylene 
protons attached to the oxygen atom are more deshielding, therefore they display 
a resonance signal (singulet) that is higher field than the two benzylic methylene 
protons bonded to the nitrogen atom.  
Preparation of compounds with general structure D started from compound 20 
(Scheme 3) which was treated with a solution of bromine in CHCl3 55 affording 
the corresponding brominated derivative 21.  
 
 
 
 
 
 
 
 
 
Reagents and conditions: (a) Br2, CHCl3, r.t, overnight; (b) 1) dry DMF, CsF, r.t, 1 h; 2) p-
fluorobenzyl chloride, r.t, overnight; (c) 1) dry toluene, PPh3, Pd(OAc)2, r. t, 15 min, 2) anh. 
K2CO3, proper arylboronic acid, 100 °C, overnight. 
Scheme 3. Synthetic procedure for compounds with general structure D. 
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After, the desired N-alkylated derivative 3 was obtained by treatment of 21 with 
p-fluorobenzyl via a procedure similar to those used for previous compounds (1-
2).54 Also in this case, a chromatography separation of the two positional isomers 
3 and 4 was necessary.  
5-Aryl-2-oxo-1,2-dihydropyridine-3-carboxamide compounds 5 and 6 were 
obtained starting from the 5-bromo derivative 3 via a Suzuki-Miyaura cross-
coupling reaction56 (Figure 21) with phenylboronic acid or p-
methoxyphenylboronic acid in dry toluene using 
tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) as catalyst and anhydrous 
potassium carbonate as base, refluxing at 100 °C overnight.57 Palladium(0) 
compound required in this cycle, Pd(PPh3)4, was prepared in situ from a 
palladium(II) precursor using triphenylphosphine (PPh3) and palladium acetate 
(Pd(OAc)2).  
Compounds 5 and 6 were then purified by flash column chromatography. 
 
 
 
 
 
 
 
 
 
 
Figure 21. Suzuky cross-coupling reaction mechanism.56 
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Synthesis of 4-aryl-2-oxo-1,2-dihydropyridine derivatives 
Compounds with general structures E (Figure 19b) and F (Figure 19c) share the 
presence of an aromatic substituent (phenyl or p-methoxyphenyl) in position for 
of the pyridine nucleus.  
During my thesis work, several efforts have been made to prepare compounds 
with general structure E, 7-8. Initially the synthesis of these compounds was 
planned starting from 4-aryl-1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-
carbonitrile which, after being hydrolyzed to the corresponding carboxylic acid, 
would be easly converted into the desired carboxamide derivatives 7 and 8 
(Figure 22).  
 
 
 
 
 
 
 
 
 
 
3-cyano-2-pyridones 29-30 were easly obtained using modified Kibou’s 
synthetic procedure58 depicted in Scheme 4. Ethyl 2-cyano-3-arylbut-2-enoate 
(30-31) were prepared by a Lewis acid-mediated Knoevenagel condensation59 of 
the opportune aromatic ketone (acetophenone 22 or p-methoxyacetophenone 23) 
Figure 22. Initial synthetic plan for preparation of compounds with general 
structure E. 
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Scheme 4. Synthetic procedure for compound 3-cyano-2-pyridones. 
with ethyl cyanoacetate 24 in presence of titanium(IV) chloride and pyridine in 
dichloromethane. After, the reaction between α,β-unsaturated compounds 25-26 
and N,N-dimethylformamide-dimethylacetal (DMF-DMA) under solvent-free 
conditions, at room temperature afforded the corresponding enaminonitriles 27-
28. Finally, cyclyzation of the enaminonitriles 27-28 with p-flurobenzylamine, at 
90 °C led to 3-cyano-2-pyridones 29-30.58 
 
 
 
 
 
 
 
 
 
Then, several attempts have been made to hydrolyze 3-cyano-2-pyridones 29-30 
to the corresponding carboxylic acid derivatives (Scheme 5). Firstly, a 
procedure53 similar to that used for converting 4-methyl-2-oxo-1,2-
dihydropyridine-3-carbonitrile 17 into its carboxylic acid derivative 18 (Scheme 
1) was carried out, treating compounds 29-30 with 50% H2SO4 at 120 °C for 8h,  
 
Reagents and conditions: (a) TiCl4, pyridine, CH2Cl2, 0 °C to r.t., overnight; (b) DMF-
DMA, solvent-free, 24 h; (c) p-fluorobenzylamine, solvent-free, 90 °C, 2 h. 
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Scheme 4. Synthetic procedure for compound 3-cyano-2-pyridones. 
 
 
 
 
 
but it failed and the starting material was recovered. Then, the same reaction was 
performed using H2SO4 of different concentrations (60%, 70% or 98%) and/or 
increasing the temperature and the reaction time, but unsuccessfully. Further 
reactions under acidic conditions were performed heating the nitrile derivatives 
with 6N HCl for 3 h60 or with concentrated HCl for 48 h, 61 but these tries were 
unfruitful once again. Since all the attempts of hydrolysis under acidic conditions 
failed, all the subsequent tries were made using basic conditions. Thus, nitrile 
derivatives 29-30 were treated with 60% ethanolic KOH refluxing for 16 h,62 and 
also with 20% aqueous NaOH refluxing for 24 h63 or heating at 140 °C in a 
microwave reactor,64 but in both the cases hydrolysis of the cyano group stopped 
at the intermediate amide stage (Figure 23).  
 
 
 
 
Figure 23. Hydrolysis of nitrile derivatives under acid or basic condition occur via amide. 
Reagents and conditions: (a) 50% H2SO4, 120 °C, 8h; (b) (60%, 70% or 98%) H2SO4, 
130-160 °C, 8-24 h; (c) 6N HCl, reflux, 3 h; (d) concentrated HCl, reflux, 48 h; (e) 60% 
KOH/EtOH, reflux, 16 h; (f) 20% aq. NaOH, reflux, 26 h or MW, 140 °C; (g) 1) 30% 
aq. H2O2, 10% NaOH, EtOH, 23 °C to 50 °C, 18 h; 2) 10% KOH, reflux, 20 h. 
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The last attempt was performed by a two-step procedure, which involved initial 
peroxide-mediated conversion of the nitrile mojety to the corresponding primary 
amide65, 66 and the subsequent extended exposure of the resulting amide to 
refluxing aqueous KOH, 68 but also this procedure gave unsatisfactory results.  
 
The reasons of this hydrolysis resistance that characterized the nitrile derivative 
29-30 rather than the nitrile compound 17, is probably correlated to the nature of 
the substituents in “beta” to the nitrile moiety (C4 of the pyridine ring)(Figure 
24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. a) Carbon atom in nitrile moiety has a partial positive charge; b) Aromatic 
substituents exert an electro-donating effect toward nitrile carbon atom, whereas c) methyl 
group exert electro-donating inductive effect. 
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Indeed, the phenyl group and, even more, the p-methoxyphenyl group exert 
electro-donating effects, since they are able to delocalize the partial positive 
charge of carbon atom in nitrile (Figure 24a-b), stabilizing it and, consequently, 
making the nitrile partially positive carbon less reactive toward the nucleophilic 
attack of water molecules. The methyl group in position C4 of derivative 17 exert 
only an electron-donating inductive effect (Figure 24c) that is certainly far less 
strong than electron-donating mesomeric effect. 
 
For all these reasons all the attention were focused on a recent procedure for 
obtaining the 2-pyridone scaffold with an aromatic substituent in position 4, 
developed by Krawczyk et al.67 This synthetic route is depicted on Scheme 5 and 
starts from various 3-substituted-2-chloro-pyridines (general structure I) that 
treated with freshly prepared sodium methoxide under reflux conditions in 
methanolic solutions afford the corresponding 2-methoxy substituted pyridines 
(II) via a nucleophilic substitution reaction. The N-benzylation of the pyridine 
nucleus in compounds II and to III succeeds with benzyl bromide as alkylating 
agent in toluene under reflux conditions. The 2-methoxy function in the primary 
yielded N-benzyl pyridinium cation undergo a bond cleavage by the attack of the 
bromide anion so that the alkylation reaction product finally afford a pyridine-2-
one structure (III) after the rearrangement of the pyridine nucleus bonds. The 
varying 3-substituted pyridine-2-ones are then treated with various grignards 
reagents at low temperatures, in dried THF as solvent, using copper(I) iodide as 
catalyst and lithium chloride to improve its the solubility, to afford the 
corresponding 4-aryl tetrahydropyridine-2-ones IV which are then rearomatized 
to final target structures V by heating in refluxing toluene with excess amounts 
of heat-activated manganese dioxide.  
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Scheme 5. Krawczyk’s synthetic procedure for 4-aryl-2-pyridones derivatives.67 
Reagents and conditions: (a) MeOH, NaOMe, reflux, 6 h; (b) BnBr, 120 °C, 20 h; (c) 
THF, Cu(I)I, LiCl, ArylMgBr, -40 °C to r.t, 6 h; (d) toluene, MnO2, 130 °C, 6–8 h. 
 
 
 
 
 
 
 
 
Initially I literally followed this synthetic route, starting from methyl 2-
chloropyridine-3-carboxylate 31 (Scheme 6) and using p-fluorobenzyl bromide 
as alkytating in N-alkylation rather than benzyl bromide (compound 33, Scheme 
6). Therefore, once obtained the methyl 4-aryl-2-oxo-1,2-dihydropyridine-3-
carboxylate scaffold, it would be converted into the desired N-cycloheptyl 
carboxamide derivatives 7-8 (Scheme 6). Unfortunately, the reaction with the 
Grignard reagent failed since a mixture difficult to purify was obtained.  
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Scheme 6. Second attempt for preparation of 4-aryl-2-pyridones derivatives 7-8. 
Reagents and conditions: (a) MeOH, NaOMe, reflux, 65 °C, 6 h; (b) p-fluorobenzyl 
bromide, 120 °C, 20 h; (c) dry THF, Cu(I)I, LiBr, phenylmagnesiumbromide or p-
methoxyphenylmagnesiumbromide; -40 °C to rt, 6 h. 
 
 
 
 
 
 
 
 
 
 
After, because the reported yields of the last two steps (conjugate addition and 
rearomatization) were less than 10%,67 the subsequent attempts of the addition 
reaction with the Grignard reagents were performed directly on the N-
cycloheptyl carboxamide derivatives rather than on the methyl carboxylate 
derivatives, in order to avoid a further step after the rearomatization. Thus, the N-
cycloheptyl carboxamide derivative 40 was obtained following the synthetic 
route depicted in Scheme 7.  
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Scheme 7. Synthetic route for compounds 7-8. 
Reagents and conditions: (a) 1) NaH, p-fluorobenzyl bromide, dry DMF, 50 °C, overnight; 
2) 10% NaOH, reflux, 100 °C, 4 h; (b) 1) dry DMF, DIPEA, TBTU, 0 °C, 30 min, 2) 
cycloheptylamine, 0 °C to r.t, overnight; (c) Cu(I)I, LiBr, phenylmagnesium bromide or p-
methoxyphenylmagnesium bromide, THF, -40 °C, 6 h. 
 
 
 
 
 
 
 
 
N-alkylation of the commercial available 2-hydroxynicotinic 38 acid with p-
fluorobenzyl bromide in presence of NaH, heating at 50 °C afforded the desired 
carboxylic acid 39 mixed with 3-benzyloxy ester substituted product as side 
product (not showed in th Scheme). Therefore, hydrolysis was necessary, and the 
mixture was refluxed at 100° C with 10% NaOH to ensure its complete 
conversion into the carboxylic acid derivative 39. After, it was initially treated 
with the coupling agent 2-[(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate] (TBTU) at 0 °C, in presence of N,N-diisopropylethyl amine 
(DIPEA), to afford the corresponding activated benzotriazolyl-ester (Scheme 8), 
which was added of cycloheptylamine to give the desired carboxamide derivative 
40.  
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Scheme 8. Proposed mechanism for the amide bond formation through TBTU 
activation 
 
 
 
 
 
 
 
Finally, compound 40 was treated with the proper Grignard reagent 
(phenylmagnesium bromide or p-methoxyphenylmagnesium bromide) under the 
same conditions described by Krawczyk67: using copper(I) iodide and lithium 
bromide in dried THF, at -40 °C. Surprisingly, instead of obtaining the 
corresponding 4-aryl tetrahydropyridine-2-one derivatives as described by 
Krawczyk67, after the purification of the crude residue by flash chromatography, 
the rearomatizated compounds 7-8 were obtained directly. Structure of 
compounds 7-8 was verified by 1H-NMR analysis. The spectra showed the 
absence of the signal of the aliphatic hydrogen atom at C3 and C4, and the 
consequent presence of the aromatic system (Figure 25a and 25b).  
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Figure 25a.1H-NMR spectrum of compound 7. 
 
Figure 25b. Enlargement of aromatic signals in 1H-NMR spectrum of compound 
7. 
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Scheme 9. Synthetic pathway for compounds with general structure F. 
Reagents and conditions: (a) Br2, CHCl3, r.t, overnight; (b) 1) dry toluene, PPh3, 
Pd(OAc)2, r. t, 15 min; 2) anh. K2CO3, proper arylboronic, 100 °C, overnight. 
Compounds with general structure F were prepared starting from compounds 7-
8. The synthetic pathway is showed in Scheme 9. 
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Compounds 7-8 were treated with a solution of bromine in CHCl3 to afford the 
desired compounds 8-9 which were purified by trituration with high boiling point 
petroleum ether. After, to obtained compounds 10-13, derivatives 8-9 were 
submitted to a Suzuki cross-coupling reaction under the same conditions 
previously described for compounds 5-6. Thus, toluene, triphenylphosphine and 
palladium acetate were mixed together to afford the catalyst 
tetrakis(triphenylphosphine)palladium(0). After, the catalyst was heated at 100 
°C overnight with potassium carbonate, compound 8 or 9, and with 
phenylboronic acid to afford compounds 10 and 12, or with p-
methoxyphenylboronic acid, to afford compounds 11 and 13.  
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Commercially available reagents were purchased from Sigma Aldrich or Alfa 
Aesar and used without purification. 1H-NMR spectra were recorded on a 
Bruker AVANCE III™ 400 spectrometer (operating at 400 MHz). Chemical 
shift (δ) are reported in parts per million related to the residual solvent 
signal, while coupling constants (J) are expressed in Hertz (Hz). Microwave-
assisted reactions were run in a CEM microwave synthesizer. Evaporation 
was carried out under vacuum using a rotating evaporator. The system for 
isocratic flash chromatography includes glass chromathography columns 
and silica gel 60 Å (0.040-0.063 mm; MERK) or a Buchi® Pump Module C-
601 (continuous flow of solvents up to 250ml/min at max 10bar) and 
Buchi® prepacked cartridges (silica gel 60, particle size 40-63 μm). 
Reactions was monitored by TLC on Merck aluminium silica gel (60 F254) 
plates that were visualized under a UV lamp (λ = 254 nm).  
 
Experimental part 
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2-Hydroxy-3-cyano-4-methylpyridine (17) 
 
Commercial available 4,4-dimethoxyl-2-butanone 15 (2.0 mL, 15.13 mmol) and 
cyanoacetamide 16 (1.6 g, 18.92 mmol), together with ammonium acetate (79.3 
mg), acetic acid (0.6 mL) and dry toluene (12.4 mL) were refluxed at 116° C 
with stirring for 8 h. Water generated was removed through azeotropic 
distillation using a Dean-Stark apparatus. After toluene was distilled off under 
reduced pressure at 50 °C. The residue, intermediate I, was then cooled to room 
temperature and EtOH (6.9 mL) was added at 25 °C, followed by the slow 
addition of concentrated H2SO4 (2.6 mL). The mixture was heated at 50 °C and 
stirred for 3 h. The content was cooled to 5 °C with an ice-water bath. Water (1.3 
mL) was added slowly and the reaction was left in the ice-water bath until no 
more precipitate was formed. Then, the mixture was filtered under vacuum, 
washed with ethanol and dried to give 903.9 mg (6.74 mmol) of brown solid 17.  
 
Yield: 45% 
1H-NMR: (DMSO, 400 MHz) δ (ppm) 2.31 (s, 3H, CH3), 6.24 (d, J = 7.6 Hz, 
1H, H5 Py), 8.04 (d, J = 7.6 Hz, 1H, H6 Py), 12.58 (bs, 1H, NH Py). 
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4-Methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (18) 
 
A mixture of 2-hydroxy-3-cyano-4-methylpyridine 17 (150.0 mg, 1.12 mmol) 
and 50% H2SO4 (0.2 mL) was stirred at 120 °C for 8 h. After, the reaction 
mixture was cooled to room temperature and few drops of water were added at 0 
°C. The precipitate formed was filtered under vacuum, washed with water and 
dried to afford compound 18 (83.0 mg, 0.54 mmol) as a white solid. 
 
Yield: 48% 
1H-NMR: (DMSO, 400 MHz) δ (ppm) 2.41 (s, 3H, CH3), 6.57 (d, J = 7.6 Hz, 
1H, H5 Py), 8.30 (d, J = 7.6 Hz, 1H, H6 Py), 13.33 (bs, 1H, COOH). 
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Methyl 4-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate (19) 
 
Method I:    
A mixture of 4-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid 18 (120.0 
mg, 0.78 mmol), MeOH (0.5 mL) and concentrated H2SO4 (0.2 mL) was heated 
in a microwave reactor (CEM) at 100° C for 50 minutes (power = 200 W, 
pressure = 100 psi). After cooling the mixture was neutralized with solid Na2CO3 
(pH 7-8) and extracted with CH2Cl2. The organic layer was dried over anhydrous 
Na2SO4, filtered and evaporated under reduced pressure to give compound 19 
(83.3 mg, 0.50 mmol) as a white solid.  
Method II:   
4-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid 18 (475.0 mg, 3.10 
mmol) was dissolved in MeOH (6.2 mL). Then the mixture was cooled to 0 °C 
and concentrated H2SO4 (3.1 mL) was added slowly. The reaction was refluxed 
at 85 °C overnight. After, MeOH was removed by evaporation under reduced 
pressure and solid Na2CO3 was added until a pH of 7-8 was reached. The mixture 
was then extracted with CH2Cl2, dried over anhydrous Na2SO4, filtered and 
evaporated under vacuum to afford compounds 19 (409.3 mg, 2.47 mmol) as a 
white solid. 
 
Yield: 80% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 2.48 (s, 3H, CH3), 3.90 (s, 3H, COOCH3), 
6.28 (d, J = 7.6 Hz, 1H, H5 Py), 8.20 (d, J = 7.6 Hz, 1H, H6 Py). 
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N-Cycloheptyl-4-Methyl-2-oxo-1,2-dihydropyridine-3-
carboxamide (20) 
 
Method I:  
Methyl 4-Methyl-2-oxo-1,2-dihydropyridine-3-carboxylate 19 (187.0 mg, 1.13 
mmol) was suspended in cyclohepthylamine (0.5 mL, 3.67 mmol) was heated in 
a microwave reactor (CEM) at 130° C for 30 minutes (power = 140 W, pressure 
= 100 psi). After cooling to room temperature, the reaction mixture was kept in 
an ice-water bath and treated with 10% HCl until a pH of 1-2 was reached. The 
precipitated formed was collected by filtration, washed with water and dried 
under vacuum to afford compound 20 (80.0 mg, 0.32 mmol) as a white solid. 
Method II:   
A suspension of methyl 4-Methyl-2-oxo-1,2-dihydropyridine-3-carboxylate 19 
(964.0 mg, 5.81 mmol) in cyclohepthylamine (2.2 mL, 17.49 mmol) was 
refluxed at 150° C for 48 h. The mixture was cooled in an ice-water bath and 
10% HCl was added until to pH 1-2. After that the white solid compound was 
collected by filtration, washed with water and dried under vacuum to give 440.0 
mg of compound 20 (1.78 mmol). 
 
Yield: 31% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.51-1.98 (m, 12H, cycloheptyl), 2,45 (s, 
3H, CH3), 4.17-4.27 (m, 1H, NH-CH cycloheptyl), 6.36 (d, J = 7.6 Hz, 1H, H5 
Py), 8.55 (d, J = 7.6 Hz, 1H, H6 Py), 9.63 (bd, 1H, CONH), 12.96 (bs, 1H, NH 
Py) .  
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N-cycloheptyl-1-(4-fluorobenzyl)-4-methyl-2-oxo-1,2-
dihydropyridine-3-carboxamide (1) and N-cycloheptyl-2-((4-
fluorobenzyl)oxy)-4-methylnicotinamide (2) 
 
N-Cycloheptyl-4-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 20 (75.0 mg, 
0.30 mmol) was solubilized in anhydrous DMF (0.9 mL) and after CsF (138.5 
mg, 0.91 mmol) was added. The mixture was stirred at room temperature for 1 h.  
Then, p-fluorobenzyl chloride (0.1 mL, 0.91 mmol) was added and the mixture 
obtained was stirred at 25 °C overnight. The reaction mixture was treated with 
ice-water and then repeatedly extracted with CH2Cl2. The combined organic 
layers were dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure to give a crude residue, which was purified by flash column 
chromatography on silica gel using, as eluent, a gradient mixture of petroleum 
ether/ethyl acetate from 8:2 to 5:5, affording compound 1 (57.2 mg, 0.16 mmol) 
as a brown oil and compound 2 (21.6 mg, 0.06 mmol) as a white-yellow solid.  
 
Yield (1): 53% 
1H-NMR (1): (CDCl3, 400 MHz) δ (ppm) 1.48 - 2.03 (m, 12H, cycloheptyl), 2.35 
(s, 3H, CH3), 4.12-4.13 (m, 1H, NH-CH cycloheptyl), 5.35 (s, 2H, N-CH2), 6.30 
(d, J = 7.6 Hz, 1H, H5 Py), 6.99-7.11 (m, 4H, ArH), 8.45 (d, J = 7.6 Hz, 1H, H6 
Py), 9.72 (bd, 1H, CONH).  
13C-NMR (1): (CDCl3, 100 MHz) δ (ppm) 21.42, 24.56, 28.44, 35.27, 47.40, 
50.72, 116.17, 116.39, 119.36, 128.33, 131.48, 143.35, 150.59, 161.29, 163.44, 
163.74.  
 
Yield (2): 20% 
1H-NMR (2): (CDCl3, 400 MHz) δ (ppm) 1.40-1.63 (m, 12H, cycloheptyl), 2.50 
(s, 3H, CH3), 4.10-4.20 (m, 1H, NH-CH cycloheptyl), 5.43 (s, 2H, O-CH2), 6.91 
(d, J = 8.0 Hz, 1H, H5 Py), 7.08-7.48 (m, 4H, ArH), 8.40 (d, J = 8.0 Hz, 1H, H6 
Py).  
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5-Bromo-N-cycloheptyl-4-methyl-2-oxo-1,2-dihydropyridine-3-
carboxamide (21) 
 
N-cycloheptyl-4-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 20 (440.0 
mg, 1.78 mmol) was dissolved in CHCl3 (3.0 mL). Then a solution of Br2 (0.1 
mL, 1.78 mmol) in CHCl3 (1.8 mL) was added dropwise to the mixture. The 
solution was stirred at room temperature overnight. 
After the mixture was diluted with CHCl3 and washed two times with saturated 
solution of Na2S2O3. Then the organic phase was dried over anhydrous Na2SO4, 
filtered and evaporated under reduce pressure. The brown solid obtained was 
triturated with high boiling point petroleum ether to afford pure compound 21 
(573.0 mg, 1.75 mmol). 
 
Yield: 99% 
1 H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.61 (m, 12H, cycloheptyl), 2.53 (s, 3H, 
CH3), 4.19 (m, 1H, NH-CH cycloheptyl), 8.65 (s, 1H, H6 Py), 9.45 (bd, 1H, 
CONH), 13.40 (bs, 1H, NH Py). 
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5-Bromo-N-cycloheptyl-1-(4-fluorobenzyl)-4-methyl-2-oxo-1,2-
dihydropyridine-3-carboxamide (3) and 5-bromo-N-cycloheptyl-
2-((4-fluorobenzyl)oxy)-4-methyl-2-oxo-1,2-dihydropyridine-3-
carboxamide (4) 
 
5-bromo-N-cycloheptyl-4-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide 21 
was dissolved in anhydrous DMF (5.5 mL) and then CsF (278.8 mg, 1.84 mmol) 
was added. The mixture was stirred at room temperature for 1 h. After p-
fluorobenzyl chloride (0.2 mL, 1.84 mmol) was added to the stirred suspension 
and the reaction was left under stirring at 25 °C, overnight.  
The reaction was treated with ice-water and then repeatedly extracted with 
CH2Cl2. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated under reduced  pressure to give a crude residue that was purified by 
flash column chromatography on silica gel using the mixture petroleum 
ether/ethyl acetate 9:1 as eluent, affording the compound 3 (84.9 mg, 0.20 mmol) 
as a brown oil and compound 4 (108.0 mg, 0.25 mmol) as a white-brown solid. 
 
Yield (3): 32% 
1H-NMR (3): (CDCl3, 400 MHz) δ (ppm) 1.51 - 1.68 (m, 12H, cycloheptyl), 2.53 
(s, 3H, CH3), 4.12-4.17 (m, 1H, NH-CH cycloheptyl), 5.43 (s, 2H, N-CH2), 7.03 
-7.13 (m, 4H, ArH), 8.66 (s, 1H, H6 Py), 9.61 (bd, 1H, CONH); 
13C-NMR (3): (CDCl3, 100 MHz) δ 21.15, 24.50, 28.44, 31.28, 49.02, 50.85, 
102.18, 116.57, 128.27, 128.35, 130.96, 130.99, 161.40, 162.40, 163.85. 
 
Yield (4): 41% 
1H-NMR (4): (CDCl3, 400 MHz) δ (ppm) 1.37-1.86 (m, 12H, cycloeptyl), 2.61 
(s, 3H, CH3), 4.10-4.15 (m, 1H, NH-CH cycloheptyl), 5.42 (s, 2H, O-CH2), 7.09-
7.48 (m, 4H, ArH), 8.57 (s, 1H, H6 Py). 
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N-Cycloheptyl-1-(4-fluorobenzyl)-4-methyl-2-oxo-5-phenyl-1,2-
dihydropyridine-3-carboxamide (5) 
 
Dry toluene (1.7 mL) was placed in a vial together with PPh3 (6.7 mg, 0.0255 
mmol) and Pd(OAc)2 (1.2 mg, 0,0051 mmol). Then the mixture was stirred at 
room temperature for 15 minutes to allow the formation of the catalyst tetrakis 
(triphenylphosphine)-palladium(0). After 5-bromo-N-cycloheptyl-1-(4-
fluorobenzyl)-2-oxo-4-methyl-1,2-dihydropyridine-3-carboxamide 3 (75.0 mg, 
0.17 mmol), anhydrous K2CO3 (35.9 mg, 0.26 mmol) and phenyl boronic acid 
(42.5 mg, 0.34 mmol) were added to the mixture. The reaction was heated at 100 
°C under stirring, overnight. 
After the reaction mixture was purified by flash column chromatography on 
silica gel, using a mixture of petroleum ether/ ethyl acetate (7:3) as eluent 
solvent. The proper fractions were collected and evaporated affording pure 
compound 5 (87.1 mg, 0.20 mmol) as a yellow oil. 
 
Yield: > 99% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.53-1.69 (m, 12H, cycloheptyl), 2.30 (s, 
3H, CH3), 4.11-4.13 (m, 1H, NH-CH cycloheptyl), 5.46 (s, 2H, N-CH2), 7.04-
7.42 (m, 9H, ArH), 8.51 (s, 1H, H6 Py). 
13C-NMR: (CDCl3, 400 MHz) δ (ppm) 14.53, 24.52, 28.47, 31.27, 50.66, 50.75, 
116.24, 122.29, 128.23, 128.97, 132.39, 161.30, 163.75, 171.51.  
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N-Cycloheptyl-1-(4-fluorobenzyl)-5-(4-methoxyphenyl)-4-
methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (6) 
 
Dry toluene (1.2 mL) was placed in a vial together with PPh3 (5.0 mg, 0.019 
mmol) and Pd(OAc)2 (0.9 mg, 0,004 mmol). Then the mixture was stirred at 
room temperature for 15 minutes to allow the formation of the catalyst tetrakis 
(triphenylphosphine)-palladium(0). After 5-bromo-N-cycloheptyl-1-(4-
fluorobenzyl)-2-oxo-4-methyl-1,2-dihydropyridine-3-carboxamide 3 (54.8 mg, 
0.13 mmol), anhydrous K2CO3 (26.1 mg, 0.19 mmol) and p-methoxyphenyl 
boronic acid (38.3 mg, 0.25 mmol) were added to the mixture. The reaction was 
heated at 100 °C under stirring, overnight. 
After the reaction mixture was purified by flash chromatography using Buchi® 
pre-packed silica cartridges (mass = 4 g, particle size = 40-63 µm, flow = 20 
mL/min) and a mixture of ethyl acetate/petroleum ether (2:8) as eluent solvent, 
affording 32.5 mg of compound 6 (0.07 mmol) as yellow-brown oil. 
 
Yield: 54% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.53-1.67 (m, 12H, cycloheptyl), 2.17 (s, 
3H, OCH3), 2.30 (s, 3H, CH3), 4.11-4.13 (m, 1H, NH-CH cycloheptyl), 5.40 (s, 
2H, N-CH2), 7.01-7.459 (m, 9H, ArH), 8.50 (s, 1H, H6 Py). 
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(E)-3-Oxo-2-(1-phenylethylidene) pentanenitrile (25) 
 
Commercial available acetophenone 22 (1.2 mL, 10.05 mmol) and ethyl 
cyanoacetate 24 (1.3 mL, 12.06 mmol) were dissolved in dry CH2Cl2 (40.0 mL) 
and cooled to 0 °C in an ice bath. Neat TiCl4 (2.2 mL, 20.10 mmol) was added 
dropwise to the solution. After this addition, the mixture was stirred for 30 
minutes, and then dry pyridine (0.7 mL) was added dropwise always at 0 °C. The 
ice bath was subsequently removed and the solution was stirred at room 
temperature for 1 h. A further aliquot of dry pyridine (2.0 mL) was added 
dropwise and the mixture was stirred at room temperature overnight. 3 M HCl 
(40.0 mL) was added to the mixture and the organic layer separated. The 
acqueous layer was further extracted with CH2Cl2 (2 x 10.0 mL) and the 
combinated organics were washed with water and finally brine, and after dried 
over anhydrous Na2SO4, filtered and concentrated to give compound 25 (2.3 g, 
10.60 mmol) as a viscous amber oil, which was used for the next step without 
further purification. 
 
Yield: > 99% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.38 (t, J = 7.2 Hz, 3H, OCH2CH3), 2.70 
(s, 3H, CH3), 4.34 (q, J = 14.4 Hz, 2H, OCH2CH3), 7.43-7.47 (m, 5H, ArH). 
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(E)-2-(1-(4-Methoxyphenyl)ethylidene)-3-oxo-pentanenitrile 
(26) 
 
Commercial available p-methoxyacetophenone 23 (1.5 g, 10.05 mmol) and ethyl 
cyanoacetate 24 (1.3 mL, 12.06 mmol) were dissolved in dry CH2Cl2 (40.0 mL) 
and cooled to 0°C in an ice bath. Neat TiCl4 (2.2 mL, 20.10 mmol) was added 
dropwise to the solution. After this addition, the mixture was stirred for 30 
minutes, and then dry pyridine (0.7 mL) was added dropwise always at 0 °C. The 
ice bath was subsequently removed and the solution was stirred at room 
temperature for 1 h. A further aliquot of dry pyridine (2.0 mL) was added 
dropwise and the mixture was stirred at room temperature overnight. 3 M HCl 
(40.0 mL) was added to the mixture and the organic layer separated. The 
acqueous layer was further extracted with CH2Cl2 (2 x 10.0 mL) and the 
combinated organics were washed with water and finally with brine, and after 
dried over anhydrous Na2SO4, filtered and concentrated to give compound 26 
(5.3 g, 21.71 mmol) as a viscous amber oil, which was used for the next step 
without further purification. 
 
Yield: > 99% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.38 (t, J = 7.2 Hz, 3H, OCH2CH3), 3.83 
(s, 3H, CH3), 3.85 (s, 3H, OCH3), 4.33 (q, J = 7.2 Hz, 2H, OCH2CH3), 6.95-7.48 
(m, 4H ArH). 
 
 
80 
 
(2E,4E)-5-(Dimethylamino)-3-phenyl-2-propionylpenta-2,4-
dienenitrile (27) 
 
A mixture of (E)-3-oxo-2-(1-phenylethylidene)pentanenitrile 25 (1.0 g, 4.65 
mmol) and N,N-dimethylformamide-dimethyl acetal (0.6 mL, 4.65 mmol) was 
stirred at room temperature without any solvent for 24 h. The purple solid 
obtained was triturated several times with diethyl ether and, at last, the solid was 
filtered under vacuum to afford compound 27 (835.5 mg, 3.09 mmol) as a yellow 
solid, which was used for the next step without further purification. 
 
Yield: 67% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.34 (t, J = 7.2 Hz, 3H, OCH2CH3), 3.00 
(s, 6H, N(CH3)2), 4.26 (q, J = 7.2 Hz, 2H, OCH2CH3), 6.51 (d, J = 12.8 Hz, 1H, 
CH=CH), 7.21 (d, J = 12.8 Hz, 1H, CH=CH), 7.24-7.41 (m, 5H, ArH).    
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(2E,4E)-5-(Dimethylamino)-3-(4-methoxyphenyl)-2-
propionylpenta-2,4-dienenitrile (28) 
 
A mixture of (E)-2-(1-(4-methoxyphenyl)ethylidene)-3-oxo-pentanenitrile 26 
(2.7 g, 10.85 mmol) and N,N-dimethylformamide-dimethyl acetal (1.4 mL, 10.85 
mmol) was stirred at room temperature without any solvent for 24 h. The purple 
solid obtained was triturated several times with diethyl ether and then filtered 
under vacuum affording compound 28 (1.7 g, 5.82 mmol) as a yellow-green 
solid, which was used for the next step without further purification. 
 
Yield: 54% 
1H-NMR: (DMSO, 400 MHz) δ (ppm) 1.26 (t, J = 7.2 Hz, 3H, OCH2CH3), 3.01 
(s, 3H, N-CH3), 3.08 (s, 3H, N-CH3), 3.85 (s, 3H, OCH3), 4.17 (q, J = 6.8 Hz, 
2H, OCH2CH3), 6.75 (d, J = 12.4 Hz, 1H, CH=CH), 7.12 (d, J = 12.8 Hz, 1H, 
CH=CH), 7.02-7.20 (m, 4H, ArH). 
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1-(4-Fluorobenzyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-
carbonitrile (29) 
 
A mixture of (2E,4E)-5-(dimethylamino)-3-phenyl-2-propionylpenta-2,4-
dienenitrile 27 (271.5 mg, 1.00 mmol) and p-flurobenzylamine (0.1 mL, 1.00 
mmol) was refluxed at 90 °C for 2 h. After cooling, the solid obtained was 
triturated several times with diethyl ether to give compound 29 (251.0 mg, 0.82 
mmol) as a brown solid. 
 
Yield: 82% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 2.55 (s, 2H, N-CH2), 6.63 (d, J = 6.8 Hz, 
1H, H5 Py), 7.23-7.71 (m, 9H, ArH), 8.35 (d, J = 7.2 Hz, 1H, H6 Py). 
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1-(4-Fluorobenzyl)-4-(4-methoxyphenyl)-2-oxo-1,2-
dihydropyridine-3-carbonitrile (30) 
 
A mixture of (2E,4E)-5-(dimethylamino)-3-(4-methoxyphenyl)-2-
propionylpenta-2,4-dienenitrile 28 (144.8 mg, 0.48 mmol) and p-
flurobenzylamine (0.1 mL, 0.48 mmol) was refluxed at 90 °C for 2 h. After 
cooling, the solid obtained was was triturated several times with diethyl ether to 
give compound 30 (125.0 mg, 0.37 mmol) as a brown solid.  
 
Yield: 78%  
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 3.86 (s, 3H, OCH3), 5.14 (s, 2H, N-CH2), 
6.32 (d, J = 6.8 Hz, 1H, H5 Py), 7.00-7.09 (m, 4H, ArH), 7.36 - 7.62 (m, 4H, 
ArH), 7.48 (d, J = 6.8 Hz, 1H, H6 Py). 
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Methyl-2-methoxynicotinate (32) 
 
Sodium (296.0 mg, 12.88 mmol) was added to dried methanol (8.0 mL). After 
the dissolvation of sodium, commercial available methyl-2-chloro-pyridine-3-
carboxylate (31) (1.5 mL, 11.66 mmol) was added and the mixture was refluxed 
at 65 °C for 6 h. Then water and ethyl acetate were added to the solution and the 
organic layer was separated. The water layer was extracted with ethyl acetate for 
three times. The organic phases were unified and dried over anhydrous Na2SO4, 
filtered and evaporated, affording compound 32 (1.6 g, 9.72 mmol) as a colorless 
oil that was used for the next step without further purification. 
 
Yield: 83% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 3.90 (s, 3H, OCH3), 4.04 (s, 3H, 
COOCH3), 6.94 (m, 1H, H5 Py), 8.16 (dd, J1 = 6 Hz, J2 = 2 Hz, 1H, H6 Py), 8.31 
(dd, J1 = 5.2 Hz, J2 = 2.0 Hz, 1H, H4 Py). 
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Methyl 1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-
carboxylate (33) 
 
Methyl 2-methoxynicotinate 32 (420.5 mg, 2.52 mmol) was dissolved in p-
fluorobenzyl bromide (0.4 mL, 3.20 mmol) under heating and the solution was 
further heated at 120 °C for 20 h.  
After, pure compound 33 (589.7 mg, 2.26 mmol) was obtained by purification by 
flash column chromatography of the final reaction mixture over silica gel and 
petroleum ether/ ethyl acetate (6:4) as eluent mixture. 
 
Yield: 90% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 3.90 (s, 3H, OCH3), 5.13 (s, 2H, N-CH2), 
6.24 (t, J = 7.2 Hz, 1H, H5 Py), 7.00-7.38 (m, 4H, ArH), 7.53 (dd, J1 = 6.4 Hz, J2 
= 2 Hz, 1H, H6 Py), 8.15 (dd, J1 = 7.2 Hz, J2 = 2.4 Hz, 1H, H4 Py). 
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Methyl 1-(4-fluorobenzyl)-2-oxo-4-phenyl-1,2,3,4-
tetrahydropyridine-3-carboxylate (34) 
 
Methyl 1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 33 (294.0 
mg, 1.13 mmol) was dissolved in dry THF (6.5 mL). Copper(I) iodide (41.9 mg, 
0.22 mmol) and lithium bromide (19.1 mg, 0.22 mmol) were added under 
nitrogen atmosphere and the solution was cooled down to -40°C.  
The phenylmagnesium bromide (1 M in THF, 1.8 mL, 1.82 mmol) was added 
dropwise, always under nitrogen. After additional 6 h the stirred solution was 
warmed up to room temperature. After a 20% solution of ammonium chloride 
(5.5 mL) and diethyl ether (6.9 mL) were added. The organic phase was 
separated and the water layer was extracted two times with diethyl ether (2 x 
6.92 mL). The organic phases were unified and washed with 20% solution of 
ammonium chloride (13.8 mL), water (13.8 mL), twice with a 10% solution of 
hydrochloric acid (2 x 13.8 mL), water (13.8 mL) and brine. After the organic 
layer was dried over anhydrous Na2SO4, filtered and evaporated, affording a 
mixture difficult to purify. Therefore compound 34 was not isolated. 
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1-(4-Fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 
(39) 
 
Commercial available 2-hydroxynicotinic acid 38 (1.5 g, 10.78 mmol) was 
dissolved in anhydrous DMF (20.0 mL) and then NaH (650.0 mg, 27.08 mmol) 
was slowly added. The mixture was left under stirring at room temperature for 1 
h. After p-fluorobenzyl chloride (1.5 mL, 12.52 mmol) was added and the 
mixture was heated at 50 °C overnight.  
Then, DMF was removed under reduced pressure affording a white solid that 
was triturated several times with water and then filtered under vacuum.  
To the solid obtained from the previous step a solution of 10 % NaOH (20.0 mL) 
was added and the mixture was refluxed at 100 °C for 4 h. Then the mixture was 
acidified with concentrated HCl until a pH 1-2 was reached, and the precipitated 
formed was filtered under vacuum, washed with water and dried under vacuum 
to afford pure compound 39 (2.6 g, 10.36 mmol). 
   
Yield: 96% 
1H-NMR: (DMSO, 400 MHz) δ (ppm) 5.34 (s, 2H, N-CH2), 6.81 (t, J = 7.2 Hz, 
1H, H5 Py), 7.22-7.50 (m, 4H, ArH), 8.42-8.47 (m, 2H, H4 and H6 Py). 
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N-Cycloheptyl-1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-
carboxamide (40) 
 
1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid 39 (3.4 g, 13.76  
mmol) was dissolved in dried DMF (40.0 mL). After DIPEA (7.2 mL, 41.28 
mmol) and TBTU (4.4 g, 13.76 mmol) were added at 0 °C, under N2, and the 
reaction was left at 0 °C for 30 minutes. After, cycloheptylamine (1.8 mL, 13.76 
mmol) was added at 0 °C and the mixture was left at room temperature 
overnight. After evaporation of the solvent, the crude solid obtained was purified 
by flash column chromatography on silica gel using the mixture ethyl 
acetate/petroleum ether (6:4) as eluent. After evaporation of the opportune 
fraction, pure compound 40 (3.3 g, 9.70 mmol) as a brown oil. 
 
Yield: 71%  
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.53-2.02 (m, 12H, cycloheptyl), 4.11-
4.16 (m, 1H, NH-CH cycloheptyl), 5.18 (s, 2H, CH2), 6.40 (t, J = 6.8 Hz, 1H, H5 
Py), 7.03-7.29 (m, 4H, ArH), 7.47 (dd, J1 = 6.8 Hz, J2 = 2.4 Hz, 1H, H6 Py), 8.53 
(dd, J1 = 7.2 Hz, J2 = 2.4 Hz, 1H, H4 Py). 
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N-Cycloheptyl-1-(4-fluorobenzyl)-2-oxo-4-phenyl-1,2-
dihydropyridine-3-carboxamide (7) 
 
N-Cycloheptyl-1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 40 
(1.3 g, 3.86 mmol) was dissolved in dry THF (28.2 mL), and copper(I) iodide 
(143.4 mg, 0.75 mmol) was added under nitrogen atmosphere, followed by 
lithium bromide (65.4 mg, 0.75 mmol). After, the stirred solution was cooled to -
40 °C and phenylmagnesium bromide (1 M in THF, 7.72 mL, 6.18 mmol) was 
added dropwise, always under nitrogen. The reaction mixture was then left under 
stirring at -40 °C After additional 6 h the stirred solution was warmed up to room 
temperature. After a 20% solution of ammonium chloride (19.0 mL) and diethyl 
ether (24 mL) were added. The organic phase was separated and the water layer 
was extracted two times with diethyl ether (2 x 24 mL). The organic phases was 
collected and washed with 20% solution of ammonium chloride (45 mL), water 
(45 mL), twice with a 10% solution of hydrochloric acid (2 x 45 mL), water (45 
mL) and brine. After the organic layer was was dried over anhydrous Na2SO4, 
filtered and evaporated to afford a crude residue that was purified by flash 
column chromatography on silica gel, using a mixture of toluene/ ethyl acetate 
(3:7) as eluent solvent. The proper fractions were collected and evaporated, 
afforded compound 7 (1.5 g, 3.55 mmol) as a brown oil. 
 
Yield: 92% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.25-1.89 (m, 12H, cycloheptyl), 3.97-
3.99 (m, 1H, NH-CH cycloheptyl), 5.15 (s, 2H, N-CH2), 6.23 (d, J = 7.2 Hz, 1H, 
H5 Py), 7.03-7.45 (m, 9H, ArH), 7.46 (d, J = 7.2 Hz, 1H, H6 Py). 
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N-Cycloheptyl-1-(4-fluorobenzyl)-4-(4-methoxyphenyl)-2-oxo-
1,2-dihydropyridine-3-carboxamide (8) 
 
N-Cycloheptyl-1-(4-fluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 40 
(2.0 g, 5.84 mmol) was dissolved in dry THF, and copper(I) iodide (216,9 mg, 
1.14 mmol) was added under nitrogen atmosphere, followed by lithium bromide 
(98.9 mg, 1.14 mmol). After, the stirred solution was cooled to -40 °C and p-
methoxyphenylmagnesium bromide (0.5 M in THF, 19.7 mL, 9.34 mmol) was 
added dropwise, always under nitrogen. The reaction mixture was then left under 
stirring at -40 °C After additional 6 h the stirred solution was warmed up to room 
temperature. After a 20% solution of ammonium chloride (28.0 mL) and diethyl 
ether (36.0 mL) were added. The organic phase was separated and the water layer 
was extracted two times with diethyl ether (2*36.0 mL). The organic phases was 
collected and washed with 20% solution of ammonium chloride (69.0 mL), water 
(69.0 mL), twice with a 10% solution of hydrochloric acid (2*69.0 mL), water 
(69.0 mL) and brine. After the organic layer was was dried over anhydrous 
Na2SO4, filtered and evaporated to afford a crude residue that was purified by 
flash column chromatography on silica gel using a mixture of ethyl 
acetate/petroleum ether (7:3) as eluent solvent. The proper fractions were 
collected and evaporated, afforded compound 8 (352.1 mg, 0.79 mmol) as a 
brown oil. 
 
Yield: 13% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.40-1.58 (m, 12H, cycloheptyl), 3.45-
3.50 (m, 1H, NH-CH cycloheptyl), 3.82 (s, 3H, OCH3), 5.14 (s, 2H, N-CH2), 
6.23 (d, J = 6.8 Hz, 1H, H5 Py), 6.89-7.07 (m, 4H, ArH), 7.29-7.35 (m, 5H, H6 
Py and ArH). 
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5-Bromo-N-cycloheptyl-1-(4-fluorobenzyl)-2-oxo-4-phenyl-1,2-
dihydropyridine-3-carboxamide (9) 
 
N-Cycloheptyl-1-(4-fluorobenzyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-
carboxamide 7 (191.0 mg, 0.46 mmol) was dissolved in CHCl3 (0.8 mL). A 
solution of Br2 (0.02 mL, 0.46 mmol) in CHCl3 (0.5 mL) was then added 
dropwise and the mixture was left under stirring at room temperature overnight. 
After the mixture was diluted with CHCl3 and washed two times with a saturated 
solution of Na2S2O3 . The organic layer was then dried over anhydrous Na2SO4, 
filtered and evaporated under reduce pressure. The brown solid obtained was 
triturated with high boiling point petroleum ether to afford pure compound 9 
(142.1 mg, 0.29 mmol). 
 
Yield: 63% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.36-1.74 (m, 12H, cycloheptyl), 3.87-
3.89 (m, 1H, NH-CH cycloheptyl), 5.13 (s, 2H, N-CH2), 7.06-7.43 (m, 9H, ArH), 
7.60 (s, 1H, H6 Py).  
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5-Bromo-N-cycloheptyl-1-(4-fluorobenzyl)-4-(4-
methoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (10) 
 
N-Cycloheptyl-1-(4-fluorobenzyl)-4-(4-methoxyphenyl)--2-oxo-1,2-
dihydropyridine-3-carboxamide 8 (315.7 mg, 0.70 mmol) was dissolved in 
CHCl3 (1.2 mL). A solution of Br2 (0.036 mL, 0.70 mmol) in CHCl3 (0.7 mL) 
was then added dropwise and the mixture was left under stirring at room 
temperature overnight. 
After the mixture was diluted with CHCl3 and washed two times with a saturated 
solution of Na2S2O3 . The organic layer was then dried over anhydrous Na2SO4, 
filtered and evaporated under reduce pressure. The brown solid obtained was 
triturated with high boiling point petroleum ether to afford pure compound 10 
(400.0 mg, 0.75 mmol). 
 
Yield: > 99% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.21-1.54 (m, 12H, cycloheptyl), 3.81 (s, 
3H, OCH3), 3.82-3.98 (m, 1H, NH-CH cycloheptyl), 5.11 (s, 2H, N-CH2), 6.91-
7.40 (m, 8H, ArH), 7.59 (s, 1H, H6 Py). 
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N-Cycloheptyl-1-(4-fluorobenzyl)-2-oxo-4,5-diphenyl-1,2-
dihydropyridine-3-carboxamide (11) 
 
Dry toluene (2.5 mL) was placed in a vial together with PPh3 (10.2 mg, 0.039 
mmol) and Pd(OAc)2 (1.9 mg, 0.0078 mmol). Then the mixture was stirred at 
room temperature for 15 minutes to allow the formation of the catalyst 
tetrakis(triphenylphosphine)-palladium(0). After, 5-bromo-N-cycloheptyl-1-(4-
fluorobenzyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carboxamide 9 (130.0 mg, 
0.26 mmol), potassium carboxylate (53.9 mg, 0.39 mmol) and phenyl boronic 
acid (65.0 mg, 0.52 mmol) were added to the mixture. The vial was sealed and 
the solution was heated at 100 °C overnight. 
After the reaction mixture was purified by flash column chromatography on 
silica gel using a mixture of ethyl acetate/petroleum ether (7:3) as eluent solvent, 
affording 117.1 mg of compound 11 (0.24 mmol) as brown oil.  
 
Yield: 91% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.38-1.51 (m, 12H, cycloheptyl), 3.90-
4.00 (m, 1H, NH-CH cycloheptyl), 5.22 (s, 2H, N-CH2), 7.06-7.51 (m, 14H, 
ArH), 7.37 (s, 1H, H6 Py). 
13C-NMR: (CDCl3, 400 MHz) δ (ppm) 24.20, 28.37, 34.93, 50.58, 52.19, 116.14, 
122.41, 127.07, 127.35, 128.33, 130.82, 130.90, 136.85, 151.95, 160.26, 164.29.
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N-Cycloheptyl-1-(4-fluorobenzyl)-4-(4-methoxyphenyl)-2-oxo-5-
phenyl-1,2-dihydropyridine-3-carboxamide (12) 
 
Dry toluene (3.6 mL) was placed in a vial together with PPh3 (14.5 mg, 0.0551 
mmol) and Pd(OAc)2 (2.7 mg, 0.011 mmol). Then the mixture was stirred at 
room temperature for 15 minutes to allow the formation of the catalyst 
tetrakis(triphenylphosphine)-palladium(0). After, 5-bromo-N-cycloheptyl-1-(4-
fluorobenzyl)-2-oxo-4-(4-methoxyphenyl)-1,2-dihydropyridine-3-carboxamide 
10 (195.0 mg, 0.37 mmol), potassium carboxylate (76.2 mg, 0.55 mmol) and 
phenyl boronic acid (91.7 mg, 0.73 mmol) were added to the mixture. The vial 
was sealed and the solution was heated at 100° C overnight. 
After the reaction mixture was purified by flash column chromatography on 
silica gel using a mixture of ethyl acetate/petroleum ether (8:2) as eluent solvent, 
affording 100.0 mg  of compound 12 (0.19 mmol) as brown oil. 
 
Yield: 51% 
1H-NMR: : (CDCl3, 400 MHz) δ (ppm) 1.39-1.64 (m, 12H, cycloheptyl), 3.50-
3.59 (m, 1H, NH-CH cycloheptyl), 3.83 (s, 3H, OCH3), 4.99 (s, 2H, N-CH2), 
6.94-7.40 (m, 13H, ArH), 8.03 (s, 1H, CONH), 8.76 (s, 1H, H6 Py). 
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N-Cycloheptyl-1-(4-fluorobenzyl)-5-(4-methoxyphenyl)-2-oxo-4-
phenyl-1,2-dihydropyridine-3-carboxamide (13) 
 
Dry toluene (3.9 mL) was placed in a vial together with PPh3 (15.8 mg, 0.0603 
mmol) and Pd(OAc)2 (3.0 mg, 0.012 mmol). Then the mixture was stirred at 
room temperature for 15 minutes to allow the formation of the catalyst 
tetrakis(triphenylphosphine)-palladium(0). After, 5-bromo-N-cycloheptyl-1-(4-
fluorobenzyl)-2-oxo-4-phenyl-1,2-dihydropyridine-3-carboxamide 9 (200.0 mg, 
0.40 mmol), potassium carboxylate (83.3 mg, 0.60 mmol) and p-methoxyphenyl 
boronic acid (122.2 mg, 0.80 mmol) were added to the mixture. The vial was 
sealed and the solution was heated at 100° C overnight. 
After the reaction mixture was purified by flash chromatography using Buchi® 
pre-packed silica cartridges (mass = 12 g, particle size = 40-63 µm, flow = 30 
mL/min) and a mixture of ethyl acetate/petroleum ether (6:4) as eluent solvent, 
affording 144.2 mg of compound 13 (0.28 mmol) as yellow-brown oil. 
 
Yield: 70%   
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.32-1.51 (m, 12H, cycloheptyl), 3.70 (s, 
3H, OCH3), 3.85-3.90 (m, 1H, NH-CH cycloheptyl), 5.17 (s, 2H, N-CH2), 6.62-
7.39 (m, 13H, ArH), 7.31 (s, 1H, H6 Py). 
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N-Cycloheptyl-1-(4-fluorobenzyl)-4,5-bis(4-methoxyphenyl)-2-
oxo-1,2-dihydropyridine-3-carboxamide (14) 
 
Dry toluene (3.6 mL) was placed in a vial together with PPh3 (14.5 mg, 0.0551 
mmol) and Pd(OAc)2 (2.7 mg, 0.011 mmol). Then the mixture was stirred at 
room temperature for 15 minutes to allow the formation of the catalyst 
tetrakis(triphenylphosphine)-palladium(0). After, 5-bromo-N-cycloheptyl-1-(4-
fluorobenzyl)-2-oxo-4-(4-methoxyphenyl)-1,2-dihydropyridine-3-carboxamide 
10 (195.0 mg, 0.37 mmol), potassium carboxylate (76.2 mg, 0.55 mmol) and p-
methoxyphenyl boronic acid (111.5 mg, 0.73 mmol) were added to the mixture. 
The vial was sealed and the solution was heated at 100° C overnight. 
After the reaction mixture was purified by flash chromatography using Buchi® 
pre-packed silica cartridges (mass = 4 g, particle size = 40-63 µm, flow = 20 
mL/min) and a mixture of ethyl acetate/petroleum ether (6:4) as eluent solvent, 
affording 73.0 mg of compound 14 (0.13 mmol) as yellow-brown oil. 
 
Yield: 35% 
1H-NMR: (CDCl3, 400 MHz) δ (ppm) 1.39-1.56 (m, 12H, cycloheptyl), 2.05 (s, 
6H, OCH3), 3.90-3.93 (m, 1H, NH-CH cycloheptyl), 5.16 (s, 2H, N-CH2), 6.65-
7.05 (m, 12H, ArH), 7.37 (s, 1H, H6 Py).   
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